Trial Outcomes & Findings for A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants (NCT NCT04263142)

Results Overview

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis. PK parameters were calculated using standard non-compartmental analysis.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

39 participants

Primary outcome timeframe

pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Results posted on

2021-03-03

Participant Flow

This was a 2-part, randomized, single dose cross-over study conducted at a single center in the United States to assess the relative bioavailability and food effect of GSK3640254 tablet and capsule formulations in healthy participants.

A total of 39 participants were enrolled in Part 1 (18 participants) and Part 2 (21 participants) of the study.

Participant milestones

Participant milestones
Measure	Part 1: Treatment Sequence AB Participants were administered a single dose of GSK3640254 200 milligram (mg) capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg tablets (Treatment B- test), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 1: Treatment Sequence BA Participants were administered a single dose of GSK3640254 200 mg tablets (Treatment B-test), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence CDE Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence DEC Participants were administered a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence ECD Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 1; followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 2; followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.
Part 1 Period 1 (Day 1) STARTED	9	9	0	0	0
Part 1 Period 1 (Day 1) COMPLETED	9	9	0	0	0
Part 1 Period 1 (Day 1) NOT COMPLETED	0	0	0	0	0
Part 1 Period 2 (Up to Day 5) STARTED	9	9	0	0	0
Part 1 Period 2 (Up to Day 5) COMPLETED	9	9	0	0	0
Part 1 Period 2 (Up to Day 5) NOT COMPLETED	0	0	0	0	0
Part 2 Period 1 (Day 1) STARTED	0	0	7	7	7
Part 2 Period 1 (Day 1) COMPLETED	0	0	7	7	6
Part 2 Period 1 (Day 1) NOT COMPLETED	0	0	0	0	1
Part 2 Period 2 (Day 1) STARTED	0	0	7	7	6
Part 2 Period 2 (Day 1) COMPLETED	0	0	7	7	5
Part 2 Period 2 (Day 1) NOT COMPLETED	0	0	0	0	1
Part 2 Period 3 (Up to Day 5) STARTED	0	0	7	7	5
Part 2 Period 3 (Up to Day 5) COMPLETED	0	0	7	7	5
Part 2 Period 3 (Up to Day 5) NOT COMPLETED	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: Treatment Sequence AB Participants were administered a single dose of GSK3640254 200 milligram (mg) capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg tablets (Treatment B- test), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 1: Treatment Sequence BA Participants were administered a single dose of GSK3640254 200 mg tablets (Treatment B-test), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence CDE Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence DEC Participants were administered a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence ECD Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 1; followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 2; followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.
Part 2 Period 1 (Day 1) Adverse Event	0	0	0	0	1
Part 2 Period 2 (Day 1) Physician Decision	0	0	0	0	1

Baseline Characteristics

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: Treatment Sequence AB n=9 Participants Participants were administered a single dose of GSK3640254 200 milligram (mg) capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg tablets (Treatment B- test), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 1: Treatment Sequence BA n=9 Participants Participants were administered a single dose of GSK3640254 200 mg tablets (Treatment B-test), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence CDE n=7 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence DEC n=7 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence ECD n=7 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 1; followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 2; followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Total n=39 Participants Total of all reporting groups
Race/Ethnicity, Customized White-White/Caucasian/European Heritage	4 Participants n=39 Participants	5 Participants n=41 Participants	4 Participants n=35 Participants	5 Participants n=31 Participants	3 Participants n=146 Participants	21 Participants n=19 Participants
Age, Customized <=18 years	0 Participants n=39 Participants	0 Participants n=41 Participants	0 Participants n=35 Participants	0 Participants n=31 Participants	0 Participants n=146 Participants	0 Participants n=19 Participants
Age, Customized 19 to 64 years	9 Participants n=39 Participants	9 Participants n=41 Participants	7 Participants n=35 Participants	7 Participants n=31 Participants	7 Participants n=146 Participants	39 Participants n=19 Participants
Age, Customized >=65 years	0 Participants n=39 Participants	0 Participants n=41 Participants	0 Participants n=35 Participants	0 Participants n=31 Participants	0 Participants n=146 Participants	0 Participants n=19 Participants
Sex: Female, Male Female	2 Participants n=39 Participants	3 Participants n=41 Participants	3 Participants n=35 Participants	1 Participants n=31 Participants	5 Participants n=146 Participants	14 Participants n=19 Participants
Sex: Female, Male Male	7 Participants n=39 Participants	6 Participants n=41 Participants	4 Participants n=35 Participants	6 Participants n=31 Participants	2 Participants n=146 Participants	25 Participants n=19 Participants
Race/Ethnicity, Customized American Indian or Alaskan Native	1 Participants n=39 Participants	0 Participants n=41 Participants	0 Participants n=35 Participants	0 Participants n=31 Participants	0 Participants n=146 Participants	1 Participants n=19 Participants
Race/Ethnicity, Customized Black or African American	4 Participants n=39 Participants	2 Participants n=41 Participants	3 Participants n=35 Participants	2 Participants n=31 Participants	4 Participants n=146 Participants	15 Participants n=19 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants n=39 Participants	1 Participants n=41 Participants	0 Participants n=35 Participants	0 Participants n=31 Participants	0 Participants n=146 Participants	1 Participants n=19 Participants
Race/Ethnicity, Customized White-Arabic/North African Heritage	0 Participants n=39 Participants	1 Participants n=41 Participants	0 Participants n=35 Participants	0 Participants n=31 Participants	0 Participants n=146 Participants	1 Participants n=19 Participants

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population comprised of all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0 to Inf]) for GSK3640254-Part 1	—	36.94 Hours*microgram per milliliter Geometric Coefficient of Variation 42.7	36.88 Hours*microgram per milliliter Geometric Coefficient of Variation 40.3

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Time t (AUC[0 to t]) for GSK3640254-Part 1	—	33.72 Hours*microgram per milliliter Geometric Coefficient of Variation 41.1	33.80 Hours*microgram per milliliter Geometric Coefficient of Variation 40.2

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Maximum Observed Concentration (Cmax) for GSK3640254-Part 1	—	1.201 Microgram per milliliter Geometric Coefficient of Variation 33.4	1.313 Microgram per milliliter Geometric Coefficient of Variation 45.3

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Time of Maximum Observed Concentration for GSK3640254-Part 1	—	5.000 Hours Interval 3.0 to 12.0	4.000 Hours Interval 2.5 to 6.0

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=10 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
AUC(0 to Inf) for GSK3640254-Part 2	36.92 Hours*micrograms per milliliter Geometric Coefficient of Variation 35.9	41.00 Hours*micrograms per milliliter Geometric Coefficient of Variation 42.2	13.46 Hours*micrograms per milliliter Geometric Coefficient of Variation 58.2

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
AUC(0 to t) for GSK3640254-Part 2	34.08 Hours*micrograms per milliliter Geometric Coefficient of Variation 34.9	37.91 Hours*micrograms per milliliter Geometric Coefficient of Variation 41.5	11.37 Hours*micrograms per milliliter Geometric Coefficient of Variation 65.6

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Cmax for GSK3640254-Part 2	1.082 Micrograms per milliliter Geometric Coefficient of Variation 38.6	1.425 Micrograms per milliliter Geometric Coefficient of Variation 35.6	0.3544 Micrograms per milliliter Geometric Coefficient of Variation 84.4

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Time of Maximum Observed Concentration for GSK3640254-Part 2	5.000 Hours Interval 1.5 to 12.0	5.000 Hours Interval 2.0 to 8.0	4.000 Hours Interval 2.03 to 24.0

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety Population comprised of all participants who received at least 1 dose of study medication.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 AEs	—	0 Participants	1 Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 SAEs	—	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 19

Population: Safety Population

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Number of Participants With AEs and SAEs-Part 2 AEs	5 Participants	0 Participants	0 Participants
Number of Participants With AEs and SAEs-Part 2 SAEs	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocytes count.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Erythrocytes Count-Part 1 Day 2; n=18, 18	—	4.937 10^12 cells per liter Standard Deviation 0.4896	4.983 10^12 cells per liter Standard Deviation 0.5010
Absolute Values for Erythrocytes Count-Part 1 Day 5; n=9, 9	—	5.009 10^12 cells per liter Standard Deviation 0.4786	5.061 10^12 cells per liter Standard Deviation 0.3888
Absolute Values for Erythrocytes Count-Part 1 Baseline; n=18, 18	—	4.801 10^12 cells per liter Standard Deviation 0.4605	4.801 10^12 cells per liter Standard Deviation 0.4605

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hemoglobin.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Hemoglobin-Part 1 Baseline; n=18, 18	—	142.2 Grams per liter Standard Deviation 13.46	142.2 Grams per liter Standard Deviation 13.46
Absolute Values for Hemoglobin-Part 1 Day 2; n=18, 18	—	146.4 Grams per liter Standard Deviation 13.74	148.3 Grams per liter Standard Deviation 14.29
Absolute Values for Hemoglobin-Part 1 Day 5; n=9, 9	—	150.3 Grams per liter Standard Deviation 15.74	150.3 Grams per liter Standard Deviation 13.13

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hematocrit.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Hematocrit-Part 1 Baseline; n=18, 18	—	0.4252 Proportion of red blood cells in blood Standard Deviation 0.03485	0.4252 Proportion of red blood cells in blood Standard Deviation 0.03485
Absolute Values for Hematocrit-Part 1 Day 2; n=18, 18	—	0.4346 Proportion of red blood cells in blood Standard Deviation 0.03935	0.4405 Proportion of red blood cells in blood Standard Deviation 0.03885
Absolute Values for Hematocrit-Part 1 Day 5; n=9, 9	—	0.4410 Proportion of red blood cells in blood Standard Deviation 0.04004	0.4430 Proportion of red blood cells in blood Standard Deviation 0.03266

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular volume.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 1 Baseline; n=18, 18	—	88.80 Femtoliters Standard Deviation 4.887	88.80 Femtoliters Standard Deviation 4.887
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 1 Day 2; n=18, 18	—	88.21 Femtoliters Standard Deviation 4.480	88.61 Femtoliters Standard Deviation 4.363
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 1 Day 5; n=9, 9	—	88.17 Femtoliters Standard Deviation 4.532	87.63 Femtoliters Standard Deviation 4.971

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular hemoglobin.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Baseline; n=18, 18	—	29.68 Picograms Standard Deviation 1.858	29.68 Picograms Standard Deviation 1.858
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Day 2; n=18, 18	—	29.69 Picograms Standard Deviation 1.740	29.83 Picograms Standard Deviation 1.772
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Day 5; n=9, 9	—	30.08 Picograms Standard Deviation 1.737	29.74 Picograms Standard Deviation 1.938

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocytes count.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Erythrocytes Count-Part 2 Baseline; n=20, 19, 21	4.613 10^12 cells per liter Standard Deviation 0.5680	4.613 10^12 cells per liter Standard Deviation 0.5680	4.613 10^12 cells per liter Standard Deviation 0.5680
Absolute Values for Erythrocytes Count-Part 2 Day 2; n=20, 19, 21	4.850 10^12 cells per liter Standard Deviation 0.5900	4.893 10^12 cells per liter Standard Deviation 0.5814	4.899 10^12 cells per liter Standard Deviation 0.5878
Absolute Values for Erythrocytes Count-Part 2 Day 5; n=7, 5, 7	4.957 10^12 cells per liter Standard Deviation 0.6309	4.941 10^12 cells per liter Standard Deviation 0.6086	4.424 10^12 cells per liter Standard Deviation 0.6683

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hemoglobin.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Hemoglobin-Part 2 Baseline; n=20, 19, 21	134.0 Grams per liter Standard Deviation 15.37	134.0 Grams per liter Standard Deviation 15.37	134.0 Grams per liter Standard Deviation 15.37
Absolute Values for Hemoglobin-Part 2 Day 2; n=20, 19, 21	140.0 Grams per liter Standard Deviation 15.37	140.6 Grams per liter Standard Deviation 15.83	141.1 Grams per liter Standard Deviation 16.19
Absolute Values for Hemoglobin-Part 2 Day 5; n=7, 5, 7	142.7 Grams per liter Standard Deviation 14.42	146.9 Grams per liter Standard Deviation 14.14	124.2 Grams per liter Standard Deviation 15.74

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hematocrit.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Hematocrit-Part 2 Baseline; n=20, 19, 21	0.4010 Proportion of red blood cells in blood Standard Deviation 0.03876	0.4010 Proportion of red blood cells in blood Standard Deviation 0.03876	0.4010 Proportion of red blood cells in blood Standard Deviation 0.03876
Absolute Values for Hematocrit-Part 2 Day 2; n=20, 19, 21	0.4176 Proportion of red blood cells in blood Standard Deviation 0.03777	0.4207 Proportion of red blood cells in blood Standard Deviation 0.03989	0.4219 Proportion of red blood cells in blood Standard Deviation 0.04146
Absolute Values for Hematocrit-Part 2 Day 5; n=7, 5, 7	0.4216 Proportion of red blood cells in blood Standard Deviation 0.03917	0.4337 Proportion of red blood cells in blood Standard Deviation 0.03499	0.3786 Proportion of red blood cells in blood Standard Deviation 0.04858

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular volume.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 2 Baseline; n=20, 19, 21	86.98 Femtoliters Standard Deviation 5.931	86.98 Femtoliters Standard Deviation 5.931	86.98 Femtoliters Standard Deviation 5.931
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 2 Day 2; n=20, 19, 21	86.57 Femtoliters Standard Deviation 5.867	86.37 Femtoliters Standard Deviation 5.934	86.52 Femtoliters Standard Deviation 6.038
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 2 Day 5; n=7, 5, 7	85.41 Femtoliters Standard Deviation 4.401	88.47 Femtoliters Standard Deviation 8.285	85.86 Femtoliters Standard Deviation 4.453

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular hemoglobin.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Baseline; n=20, 19, 21	29.05 Picograms Standard Deviation 2.499	29.05 Picograms Standard Deviation 2.499	29.05 Picograms Standard Deviation 2.499
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Day 2; n=20, 19, 21	28.99 Picograms Standard Deviation 2.411	28.87 Picograms Standard Deviation 2.415	28.92 Picograms Standard Deviation 2.449
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Day 5; n=7, 5, 7	28.93 Picograms Standard Deviation 1.962	29.96 Picograms Standard Deviation 3.365	28.14 Picograms Standard Deviation 1.394

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Day 5; n=9, 9	—	0.082 10^9 cells per liter Standard Deviation 0.2124	0.398 10^9 cells per liter Standard Deviation 0.3721
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Day 2; n=18, 18	—	-0.002 10^9 cells per liter Standard Deviation 0.0092	-0.002 10^9 cells per liter Standard Deviation 0.0092
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Day 5; n=9, 9	—	-0.002 10^9 cells per liter Standard Deviation 0.0083	-0.004 10^9 cells per liter Standard Deviation 0.0073
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Day 2; n=18, 18	—	0.006 10^9 cells per liter Standard Deviation 0.0581	0.008 10^9 cells per liter Standard Deviation 0.1164
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Day 2; n=18, 18	—	0.016 10^9 cells per liter Standard Deviation 0.0322	0.022 10^9 cells per liter Standard Deviation 0.0387
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Day 5; n=9, 9	—	0.022 10^9 cells per liter Standard Deviation 0.0441	0.029 10^9 cells per liter Standard Deviation 0.0462
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Day 2; n=18, 18	—	0.109 10^9 cells per liter Standard Deviation 0.2237	0.127 10^9 cells per liter Standard Deviation 0.2350
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Day 5; n=9, 9	—	-0.009 10^9 cells per liter Standard Deviation 0.0821	-0.001 10^9 cells per liter Standard Deviation 0.0637
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Day 2; n=18, 18	—	-0.481 10^9 cells per liter Standard Deviation 0.7029	-0.683 10^9 cells per liter Standard Deviation 0.8597
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Day 5; n=9, 9	—	-0.291 10^9 cells per liter Standard Deviation 0.5628	0.549 10^9 cells per liter Standard Deviation 0.7398
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Day 2; n=18, 18	—	5.7 10^9 cells per liter Standard Deviation 21.18	9.0 10^9 cells per liter Standard Deviation 18.89
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Day 5; n=9, 9	—	20.8 10^9 cells per liter Standard Deviation 15.16	12.8 10^9 cells per liter Standard Deviation 22.55

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Erythrocytes Count-Part 1 Day 2; n=18, 18	—	0.136 10^12 cells per liter Standard Deviation 0.2431	0.182 10^12 cells per liter Standard Deviation 0.2052
Change From Baseline in Erythrocytes Count-Part 1 Day 5; n=9, 9	—	0.253 10^12 cells per liter Standard Deviation 0.2320	0.214 10^12 cells per liter Standard Deviation 0.1729

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hemoglobin. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Hemoglobin-Part 1 Day 2; n=18, 18	—	4.2 Grams per liter Standard Deviation 7.11	6.1 Grams per liter Standard Deviation 6.69
Change From Baseline in Hemoglobin-Part 1 Day 5; n=9, 9	—	8.7 Grams per liter Standard Deviation 7.66	7.6 Grams per liter Standard Deviation 6.04

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Hematocrit-Part 1 Day 2; n=18, 18	—	0.0094 Proportion of red blood cells in blood Standard Deviation 0.02265	0.0153 Proportion of red blood cells in blood Standard Deviation 0.01912
Change From Baseline in Hematocrit-Part 1 Day 5; n=9, 9	—	0.0189 Proportion of red blood cells in blood Standard Deviation 0.02196	0.0147 Proportion of red blood cells in blood Standard Deviation 0.01362

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular volume. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Erythrocyte Mean Corpuscular Volume-Part 1 Day 2; n=18, 18	—	-0.59 Femtoliters Standard Deviation 0.984	-0.19 Femtoliters Standard Deviation 1.050
Change From Baseline in Erythrocyte Mean Corpuscular Volume-Part 1 Day 5; n=9, 9	—	-0.84 Femtoliters Standard Deviation 0.911	-0.96 Femtoliters Standard Deviation 0.592

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular hemoglobin. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Day 2; n=18, 18	—	0.01 Picograms Standard Deviation 0.344	0.14 Picograms Standard Deviation 0.365
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Day 5; n=9, 9	—	0.26 Picograms Standard Deviation 0.343	0.20 Picograms Standard Deviation 0.439

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Day 2; n=20, 19, 21	0.001 10^9 cells per liter Standard Deviation 0.0128	-0.001 10^9 cells per liter Standard Deviation 0.0107	-0.003 10^9 cells per liter Standard Deviation 0.0129
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Day 5; n=7, 5, 7	0.000 10^9 cells per liter Standard Deviation 0.0129	0.000 10^9 cells per liter Standard Deviation 0.0100	0.006 10^9 cells per liter Standard Deviation 0.0114
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Day 2; n=20, 19, 21	0.009 10^9 cells per liter Standard Deviation 0.0464	0.001 10^9 cells per liter Standard Deviation 0.0424	-0.006 10^9 cells per liter Standard Deviation 0.0519
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Day 5; n=7, 5, 7	-0.009 10^9 cells per liter Standard Deviation 0.0402	0.007 10^9 cells per liter Standard Deviation 0.0423	-0.030 10^9 cells per liter Standard Deviation 0.0738
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Day 2; n=20, 19, 21	-0.068 10^9 cells per liter Standard Deviation 0.2313	-0.073 10^9 cells per liter Standard Deviation 0.2828	0.006 10^9 cells per liter Standard Deviation 0.3097
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Day 5; n=7, 5, 7	-0.024 10^9 cells per liter Standard Deviation 0.4172	0.257 10^9 cells per liter Standard Deviation 0.2146	-0.010 10^9 cells per liter Standard Deviation 0.1454
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Day 2; n=20, 19, 21	-0.022 10^9 cells per liter Standard Deviation 0.1272	-0.028 10^9 cells per liter Standard Deviation 0.1055	-0.022 10^9 cells per liter Standard Deviation 0.0978
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Day 5; n=7, 5, 7	0.034 10^9 cells per liter Standard Deviation 0.1509	0.024 10^9 cells per liter Standard Deviation 0.1081	0.000 10^9 cells per liter Standard Deviation 0.1058
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Day 2; n=20, 19, 21	-0.300 10^9 cells per liter Standard Deviation 0.7173	-0.326 10^9 cells per liter Standard Deviation 0.7627	-0.336 10^9 cells per liter Standard Deviation 0.7377
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Day 5; n=7, 5, 7	0.134 10^9 cells per liter Standard Deviation 1.1111	-0.216 10^9 cells per liter Standard Deviation 0.6986	0.154 10^9 cells per liter Standard Deviation 0.8131
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Day 2; n=20, 19, 21	21.4 10^9 cells per liter Standard Deviation 26.82	21.6 10^9 cells per liter Standard Deviation 30.53	9.4 10^9 cells per liter Standard Deviation 25.64
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Day 5; n=7, 5, 7	-1.1 10^9 cells per liter Standard Deviation 30.28	38.0 10^9 cells per liter Standard Deviation 26.03	-5.8 10^9 cells per liter Standard Deviation 28.08

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Erythrocytes Count-Part 2 Day 2; n=20, 19, 21	0.237 10^12 cells per liter Standard Deviation 0.1682	0.256 10^12 cells per liter Standard Deviation 0.1751	0.247 10^12 cells per liter Standard Deviation 0.2564
Change From Baseline in Erythrocytes Count-Part 2 Day 5; n=7, 5, 7	0.077 10^12 cells per liter Standard Deviation 0.2276	0.231 10^12 cells per liter Standard Deviation 0.1520	0.172 10^12 cells per liter Standard Deviation 0.1678

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hemoglobin. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Hemoglobin-Part 2 Day 2; n=20, 19, 21	6.0 Grams per liter Standard Deviation 4.21	6.5 Grams per liter Standard Deviation 4.96	6.3 Grams per liter Standard Deviation 7.39
Change From Baseline in Hemoglobin-Part 2 Day 5; n=7, 5, 7	2.4 Grams per liter Standard Deviation 5.32	7.0 Grams per liter Standard Deviation 3.11	4.2 Grams per liter Standard Deviation 5.50

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Hematocrit-Part 2 Day 2; n=20, 19, 21	0.0166 Proportion of red blood cells in blood Standard Deviation 0.01313	0.0187 Proportion of red blood cells in blood Standard Deviation 0.01477	0.0182 Proportion of red blood cells in blood Standard Deviation 0.02179
Change From Baseline in Hematocrit-Part 2 Day 5; n=7, 5, 7	0.0046 Proportion of red blood cells in blood Standard Deviation 0.01855	0.0179 Proportion of red blood cells in blood Standard Deviation 0.01378	0.0106 Proportion of red blood cells in blood Standard Deviation 0.01731

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular volume. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Erythrocyte Mean Corpuscular Volume-Part 2 Day 2; n=20, 19, 21	-0.41 Femtoliters Standard Deviation 0.774	-0.35 Femtoliters Standard Deviation 0.841	-0.28 Femtoliters Standard Deviation 0.897
Change From Baseline in Erythrocyte Mean Corpuscular Volume-Part 2 Day 5; n=7, 5, 7	-0.33 Femtoliters Standard Deviation 0.834	-0.06 Femtoliters Standard Deviation 1.124	-0.02 Femtoliters Standard Deviation 1.103

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular hemoglobin. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Day 2; n=20, 19, 21	-0.06 Picograms Standard Deviation 0.356	-0.05 Picograms Standard Deviation 0.330	-0.05 Picograms Standard Deviation 0.276
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Day 5; n=7, 5, 7	0.13 Picograms Standard Deviation 0.553	0.10 Picograms Standard Deviation 0.365	0.18 Picograms Standard Deviation 0.536

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: creatinine, total bilirubin, direct bilirubin and urate.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Day 5; n=9, 9	—	79.57 Micromoles per liter Standard Deviation 17.196	80.33 Micromoles per liter Standard Deviation 11.925
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Baseline; n=18, 18	—	10.56 Micromoles per liter Standard Deviation 3.578	10.56 Micromoles per liter Standard Deviation 3.578
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Baseline; n=18, 18	—	78.68 Micromoles per liter Standard Deviation 15.983	78.68 Micromoles per liter Standard Deviation 15.983
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Day 2; n=18, 18	—	80.87 Micromoles per liter Standard Deviation 15.104	80.11 Micromoles per liter Standard Deviation 14.243
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Day 2; n=18, 18	—	11.45 Micromoles per liter Standard Deviation 4.334	10.91 Micromoles per liter Standard Deviation 2.952
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Day 5; n=9, 9	—	11.49 Micromoles per liter Standard Deviation 1.590	11.41 Micromoles per liter Standard Deviation 3.867
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Baseline; n=18, 18	—	1.96 Micromoles per liter Standard Deviation 0.624	1.96 Micromoles per liter Standard Deviation 0.624
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Day 2; n=18, 18	—	1.91 Micromoles per liter Standard Deviation 0.643	1.86 Micromoles per liter Standard Deviation 0.631
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Day 5; n=9, 9	—	1.86 Micromoles per liter Standard Deviation 0.332	1.90 Micromoles per liter Standard Deviation 0.752
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Baseline; n=18, 18	—	306.7 Micromoles per liter Standard Deviation 87.16	306.7 Micromoles per liter Standard Deviation 87.16
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Day 2; n=18, 18	—	283.2 Micromoles per liter Standard Deviation 78.74	282.5 Micromoles per liter Standard Deviation 68.93
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Day 5; n=9, 9	—	281.4 Micromoles per liter Standard Deviation 75.17	282.9 Micromoles per liter Standard Deviation 67.35

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: calcium, glucose, potassium, sodium, chloride, phosphate, BUN, triglycerides, cholesterol, anion gap and carbon dioxide.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: ALT, ALP, AST, GGT, CK and LDH.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: albumin, globulin and protein.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Baseline; n=18, 18	—	43.7 Grams per liter Standard Deviation 2.52	43.7 Grams per liter Standard Deviation 2.52
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Day 2; n=18, 18	—	43.8 Grams per liter Standard Deviation 2.53	44.4 Grams per liter Standard Deviation 2.96
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Day 5; n=9, 9	—	45.1 Grams per liter Standard Deviation 2.85	44.2 Grams per liter Standard Deviation 2.82
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Baseline; n=18, 18	—	27.5 Grams per liter Standard Deviation 3.84	27.5 Grams per liter Standard Deviation 3.84
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Day 2; n=18, 18	—	26.9 Grams per liter Standard Deviation 4.58	27.8 Grams per liter Standard Deviation 4.35
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Day 5; n=9, 9	—	26.2 Grams per liter Standard Deviation 4.58	28.0 Grams per liter Standard Deviation 4.97
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Baseline; n=18, 18	—	71.2 Grams per liter Standard Deviation 3.19	71.2 Grams per liter Standard Deviation 3.19
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Day 2; n=18, 18	—	70.7 Grams per liter Standard Deviation 5.07	72.2 Grams per liter Standard Deviation 5.43
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Day 5; n=9, 9	—	71.3 Grams per liter Standard Deviation 6.42	72.2 Grams per liter Standard Deviation 4.74

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: amylase and lipase.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Baseline; n=18, 18	—	43.3 Units per liter Standard Deviation 14.96	43.3 Units per liter Standard Deviation 14.96
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Day 2; n=18, 18	—	46.7 Units per liter Standard Deviation 18.11	47.7 Units per liter Standard Deviation 21.31
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Day 5; n=9, 9	—	44.3 Units per liter Standard Deviation 15.86	47.6 Units per liter Standard Deviation 22.94
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Baseline; n=18, 18	—	24.0 Units per liter Standard Deviation 11.24	24.0 Units per liter Standard Deviation 11.24
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Day 2; n=18, 18	—	26.7 Units per liter Standard Deviation 14.32	26.2 Units per liter Standard Deviation 14.26
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Day 5; n=9, 9	—	28.9 Units per liter Standard Deviation 14.98	24.7 Units per liter Standard Deviation 12.66

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: creatinine, total bilirubin, direct bilirubin and urate.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Baseline; n=20, 19, 21	74.00 Micromoles per liter Standard Deviation 13.855	74.00 Micromoles per liter Standard Deviation 13.855	74.00 Micromoles per liter Standard Deviation 13.855
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Day 2; n=20, 19, 21	80.18 Micromoles per liter Standard Deviation 13.533	81.95 Micromoles per liter Standard Deviation 14.968	83.34 Micromoles per liter Standard Deviation 11.078
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Day 5; n=7, 5, 7	83.71 Micromoles per liter Standard Deviation 15.520	91.69 Micromoles per liter Standard Deviation 7.992	76.04 Micromoles per liter Standard Deviation 14.435
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Baseline; n=20, 19, 21	9.05 Micromoles per liter Standard Deviation 3.070	9.05 Micromoles per liter Standard Deviation 3.070	9.05 Micromoles per liter Standard Deviation 3.070
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Day 2; n=20, 19, 21	11.11 Micromoles per liter Standard Deviation 3.517	11.49 Micromoles per liter Standard Deviation 4.185	11.88 Micromoles per liter Standard Deviation 4.544
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Day 5; n=7, 5, 7	10.46 Micromoles per liter Standard Deviation 1.397	13.34 Micromoles per liter Standard Deviation 4.999	14.30 Micromoles per liter Standard Deviation 7.174
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Baseline; n=20, 19, 21	1.89 Micromoles per liter Standard Deviation 0.660	1.89 Micromoles per liter Standard Deviation 0.660	1.89 Micromoles per liter Standard Deviation 0.660
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Day 2; n=20, 19, 21	2.07 Micromoles per liter Standard Deviation 0.656	2.12 Micromoles per liter Standard Deviation 0.747	2.17 Micromoles per liter Standard Deviation 0.732
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Day 5; n=7, 5, 7	1.87 Micromoles per liter Standard Deviation 0.431	2.29 Micromoles per liter Standard Deviation 0.760	2.38 Micromoles per liter Standard Deviation 0.996
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Baseline; n=20, 19, 21	289.2 Micromoles per liter Standard Deviation 73.13	289.2 Micromoles per liter Standard Deviation 73.13	289.2 Micromoles per liter Standard Deviation 73.13
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Day 2; n=20, 19, 21	275.4 Micromoles per liter Standard Deviation 77.75	277.7 Micromoles per liter Standard Deviation 72.39	299.4 Micromoles per liter Standard Deviation 68.62
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Day 5; n=7, 5, 7	313.6 Micromoles per liter Standard Deviation 79.74	286.3 Micromoles per liter Standard Deviation 48.83	291.2 Micromoles per liter Standard Deviation 96.66

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: calcium, glucose, potassium, sodium, chloride, phosphate, BUN, triglycerides, cholesterol, anion gap and carbon dioxide.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: ALT, ALP, AST, GGT, CK and LDH.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: albumin, globulin and protein.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Baseline; n=20, 19, 21	43.8 Grams per liter Standard Deviation 2.90	43.8 Grams per liter Standard Deviation 2.90	43.8 Grams per liter Standard Deviation 2.90
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Day 2; n=20, 19, 21	45.7 Grams per liter Standard Deviation 2.99	45.6 Grams per liter Standard Deviation 2.68	45.4 Grams per liter Standard Deviation 2.27
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Day 5; n=7, 5, 7	45.1 Grams per liter Standard Deviation 2.97	48.0 Grams per liter Standard Deviation 2.58	43.4 Grams per liter Standard Deviation 2.07
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Baseline; n=20, 19, 21	26.5 Grams per liter Standard Deviation 3.19	26.5 Grams per liter Standard Deviation 3.19	26.5 Grams per liter Standard Deviation 3.19
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Day 2; n=20, 19, 21	26.4 Grams per liter Standard Deviation 3.43	26.6 Grams per liter Standard Deviation 3.33	26.0 Grams per liter Standard Deviation 3.43
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Day 5; n=7, 5, 7	26.7 Grams per liter Standard Deviation 1.25	23.6 Grams per liter Standard Deviation 1.51	28.2 Grams per liter Standard Deviation 2.49
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Baseline; n=20, 19, 21	70.3 Grams per liter Standard Deviation 4.23	70.3 Grams per liter Standard Deviation 4.23	70.3 Grams per liter Standard Deviation 4.23
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Day 2; n=20, 19, 21	72.1 Grams per liter Standard Deviation 4.31	72.2 Grams per liter Standard Deviation 3.56	71.4 Grams per liter Standard Deviation 3.20
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Day 5; n=7, 5, 7	71.9 Grams per liter Standard Deviation 2.85	71.6 Grams per liter Standard Deviation 3.15	71.6 Grams per liter Standard Deviation 2.07

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: amylase and lipase.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Day 2; n=20, 19, 21	24.1 Units per liter Standard Deviation 11.45	20.4 Units per liter Standard Deviation 10.04	22.2 Units per liter Standard Deviation 12.81
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Baseline; n=20, 19, 21	49.3 Units per liter Standard Deviation 16.33	49.3 Units per liter Standard Deviation 16.33	49.3 Units per liter Standard Deviation 16.33
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Day 2; n=20, 19, 21	50.1 Units per liter Standard Deviation 18.22	48.3 Units per liter Standard Deviation 15.91	49.4 Units per liter Standard Deviation 18.86
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Day 5; n=7, 5, 7	43.6 Units per liter Standard Deviation 14.89	49.6 Units per liter Standard Deviation 22.33	48.8 Units per liter Standard Deviation 8.53
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Baseline; n=20, 19, 21	23.8 Units per liter Standard Deviation 17.88	23.8 Units per liter Standard Deviation 17.88	23.8 Units per liter Standard Deviation 17.88
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Day 5; n=7, 5, 7	24.1 Units per liter Standard Deviation 13.26	21.9 Units per liter Standard Deviation 9.39	17.6 Units per liter Standard Deviation 8.23

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: creatinine, total bilirubin, direct bilirubin and urate. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Day 2; n=18, 18	—	2.19 Micromoles per liter Standard Deviation 4.721	1.43 Micromoles per liter Standard Deviation 6.188
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Day 5; n=9, 9	—	3.64 Micromoles per liter Standard Deviation 3.780	-1.10 Micromoles per liter Standard Deviation 5.169
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Day 2; n=18, 18	—	0.89 Micromoles per liter Standard Deviation 2.659	0.36 Micromoles per liter Standard Deviation 2.632
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Day 5; n=9, 9	—	0.59 Micromoles per liter Standard Deviation 3.297	1.20 Micromoles per liter Standard Deviation 2.513
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Day 2; n=18, 18	—	-0.05 Micromoles per liter Standard Deviation 0.399	-0.10 Micromoles per liter Standard Deviation 0.387
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Day 5; n=9, 9	—	-0.12 Micromoles per liter Standard Deviation 0.526	-0.04 Micromoles per liter Standard Deviation 0.361
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Day 2; n=18, 18	—	-23.5 Micromoles per liter Standard Deviation 46.62	-24.2 Micromoles per liter Standard Deviation 43.16
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Day 5; n=9, 9	—	-29.8 Micromoles per liter Standard Deviation 46.45	-19.3 Micromoles per liter Standard Deviation 36.96

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: calcium, glucose, potassium, sodium, chloride, phosphate, BUN, triglycerides, cholesterol, anion gap and carbon dioxide. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: ALT, ALP, AST, GGT, CK and LDH. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 ALT; Day 2; n=18, 18	—	-0.2 International units per liter Standard Deviation 5.34	-3.6 International units per liter Standard Deviation 8.39
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 ALT; Day 5; n=9, 9	—	1.3 International units per liter Standard Deviation 7.87	-5.3 International units per liter Standard Deviation 12.32
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 ALP; Day 2; n=18, 18	—	-2.4 International units per liter Standard Deviation 5.25	-2.5 International units per liter Standard Deviation 4.74
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 ALP; Day 5; n=9, 9	—	-1.7 International units per liter Standard Deviation 7.40	-1.9 International units per liter Standard Deviation 3.37
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 AST; Day 2; n=18, 18	—	-2.6 International units per liter Standard Deviation 4.68	-4.2 International units per liter Standard Deviation 6.57
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 AST; Day 5; n=9, 9	—	-1.4 International units per liter Standard Deviation 3.84	-6.0 International units per liter Standard Deviation 8.70
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 GGT; Day 2; n=18, 18	—	-1.2 International units per liter Standard Deviation 1.93	-0.4 International units per liter Standard Deviation 2.94
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 GGT; Day 5; n=9, 9	—	-2.1 International units per liter Standard Deviation 2.47	-1.6 International units per liter Standard Deviation 3.88
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 CK; Day 2; n=18, 18	—	-39.6 International units per liter Standard Deviation 39.29	-34.8 International units per liter Standard Deviation 53.99
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 CK; Day 5; n=9, 9	—	-23.3 International units per liter Standard Deviation 28.33	-46.2 International units per liter Standard Deviation 76.08
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 LDH; Day 2; n=18, 18	—	-18.7 International units per liter Standard Deviation 11.00	-16.0 International units per liter Standard Deviation 11.86
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 LDH; Day 5; n=9, 9	—	-13.9 International units per liter Standard Deviation 16.12	-13.4 International units per liter Standard Deviation 16.13

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: albumin, globulin and protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Day 2; n=18, 18	—	0.1 Grams per liter Standard Deviation 2.80	0.7 Grams per liter Standard Deviation 3.04
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Day 5; n=9, 9	—	0.9 Grams per liter Standard Deviation 3.37	1.0 Grams per liter Standard Deviation 3.00
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Day 2; n=18, 18	—	-0.6 Grams per liter Standard Deviation 2.50	0.3 Grams per liter Standard Deviation 2.37
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Day 5; n=9, 9	—	-0.7 Grams per liter Standard Deviation 2.78	-0.1 Grams per liter Standard Deviation 1.76
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Day 2; n=18, 18	—	-0.5 Grams per liter Standard Deviation 4.82	1.0 Grams per liter Standard Deviation 4.79
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Day 5; n=9, 9	—	0.2 Grams per liter Standard Deviation 5.93	0.9 Grams per liter Standard Deviation 4.54

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: amylase and lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Day 2; n=18, 18	—	3.3 Units per liter Standard Deviation 5.66	4.3 Units per liter Standard Deviation 8.75
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Day 5; n=9, 9	—	1.0 Units per liter Standard Deviation 6.52	4.2 Units per liter Standard Deviation 6.22
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Day 2; n=18, 18	—	2.7 Units per liter Standard Deviation 8.27	2.2 Units per liter Standard Deviation 5.15
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Day 5; n=9, 9	—	4.0 Units per liter Standard Deviation 6.56	1.6 Units per liter Standard Deviation 3.28

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: creatinine, total bilirubin, direct bilirubin and urate. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Day 2; n=20, 19, 21	-13.8 Micromoles per liter Standard Deviation 32.92	-16.5 Micromoles per liter Standard Deviation 31.57	-0.5 Micromoles per liter Standard Deviation 29.49
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Day 2; n=20, 19, 21	6.18 Micromoles per liter Standard Deviation 4.833	7.25 Micromoles per liter Standard Deviation 5.306	7.41 Micromoles per liter Standard Deviation 4.836
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Day 5; n=7, 5, 7	7.19 Micromoles per liter Standard Deviation 5.827	10.10 Micromoles per liter Standard Deviation 5.536	8.86 Micromoles per liter Standard Deviation 4.565
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Day 2; n=20, 19, 21	2.06 Micromoles per liter Standard Deviation 2.729	2.29 Micromoles per liter Standard Deviation 2.650	2.47 Micromoles per liter Standard Deviation 3.448
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Day 5; n=7, 5, 7	1.69 Micromoles per liter Standard Deviation 1.791	3.89 Micromoles per liter Standard Deviation 3.133	4.04 Micromoles per liter Standard Deviation 4.689
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Day 2; n=20, 19, 21	0.18 Micromoles per liter Standard Deviation 0.494	0.21 Micromoles per liter Standard Deviation 0.524	0.22 Micromoles per liter Standard Deviation 0.550
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Day 5; n=7, 5, 7	0.11 Micromoles per liter Standard Deviation 0.389	0.31 Micromoles per liter Standard Deviation 0.495	0.16 Micromoles per liter Standard Deviation 0.611
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Day 5; n=7, 5, 7	3.3 Micromoles per liter Standard Deviation 27.67	-6.7 Micromoles per liter Standard Deviation 29.86	-4.0 Micromoles per liter Standard Deviation 34.62

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: calcium, glucose, potassium, sodium, chloride, phosphate, BUN, triglycerides, cholesterol, anion gap and carbon dioxide. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: ALT, ALP, AST, GGT, CK and LDH. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Day 2; n=20, 19, 21	-12.6 International units per liter Standard Deviation 31.50	-15.4 International units per liter Standard Deviation 27.15	-10.7 International units per liter Standard Deviation 40.57
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Day 2; n=20, 19, 21	-2.2 International units per liter Standard Deviation 8.48	-4.9 International units per liter Standard Deviation 8.61	-2.5 International units per liter Standard Deviation 4.06
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Day 5; n=7, 5, 7	5.7 International units per liter Standard Deviation 9.23	-9.7 International units per liter Standard Deviation 13.03	-3.4 International units per liter Standard Deviation 4.39
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Day 2; n=20, 19, 21	6.3 International units per liter Standard Deviation 6.21	6.1 International units per liter Standard Deviation 5.61	5.9 International units per liter Standard Deviation 5.91
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Day 5; n=7, 5, 7	-0.4 International units per liter Standard Deviation 6.50	3.9 International units per liter Standard Deviation 6.69	2.2 International units per liter Standard Deviation 6.22
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Day 2; n=20, 19, 21	-2.0 International units per liter Standard Deviation 4.88	-3.3 International units per liter Standard Deviation 5.18	-2.6 International units per liter Standard Deviation 4.40
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Day 5; n=7, 5, 7	0.6 International units per liter Standard Deviation 3.36	-5.1 International units per liter Standard Deviation 6.26	-2.8 International units per liter Standard Deviation 4.66
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Day 2; n=20, 19, 21	0.2 International units per liter Standard Deviation 3.09	-1.1 International units per liter Standard Deviation 2.65	-0.4 International units per liter Standard Deviation 1.80
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Day 5; n=7, 5, 7	2.1 International units per liter Standard Deviation 5.73	-2.4 International units per liter Standard Deviation 3.31	-1.4 International units per liter Standard Deviation 2.70
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Day 5; n=7, 5, 7	29.9 International units per liter Standard Deviation 152.85	1.1 International units per liter Standard Deviation 78.79	9.4 International units per liter Standard Deviation 92.62
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Day 2; n=20, 19, 21	-11.5 International units per liter Standard Deviation 11.97	-12.2 International units per liter Standard Deviation 10.28	-12.4 International units per liter Standard Deviation 12.05
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Day 5; n=7, 5, 7	-10.4 International units per liter Standard Deviation 15.05	-17.3 International units per liter Standard Deviation 14.95	-17.8 International units per liter Standard Deviation 3.27

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: albumin, globulin and protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Day 2; n=20, 19, 21	1.9 Grams per liter Standard Deviation 1.95	2.0 Grams per liter Standard Deviation 1.85	1.8 Grams per liter Standard Deviation 2.57
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Day 5; n=7, 5, 7	1.1 Grams per liter Standard Deviation 1.46	3.4 Grams per liter Standard Deviation 1.40	1.8 Grams per liter Standard Deviation 0.84
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Day 2; n=20, 19, 21	-0.1 Grams per liter Standard Deviation 1.76	0.2 Grams per liter Standard Deviation 1.79	-0.1 Grams per liter Standard Deviation 2.26
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Day 5; n=7, 5, 7	-1.3 Grams per liter Standard Deviation 1.80	0.1 Grams per liter Standard Deviation 1.86	0.1 Grams per liter Standard Deviation 3.39
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Day 2; n=20, 19, 21	1.8 Grams per liter Standard Deviation 3.01	2.1 Grams per liter Standard Deviation 3.01	1.7 Grams per liter Standard Deviation 4.28
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Day 5; n=7, 5, 7	-0.1 Grams per liter Standard Deviation 3.02	3.6 Grams per liter Standard Deviation 2.23	2.8 Grams per liter Standard Deviation 4.09

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: amylase and lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Day 2; n=20, 19, 21	0.8 Units per liter Standard Deviation 8.27	0.7 Units per liter Standard Deviation 5.68	1.8 Units per liter Standard Deviation 8.70
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Day 5; n=7, 5, 7	-4.4 Units per liter Standard Deviation 8.26	4.4 Units per liter Standard Deviation 4.86	-1.8 Units per liter Standard Deviation 10.16
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Day 2; n=20, 19, 21	0.3 Units per liter Standard Deviation 17.39	-2.6 Units per liter Standard Deviation 15.99	-1.4 Units per liter Standard Deviation 13.01
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Day 5; n=7, 5, 7	-9.6 Units per liter Standard Deviation 24.84	6.3 Units per liter Standard Deviation 7.54	-3.0 Units per liter Standard Deviation 14.27

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine, indicated as ratio of urine density to water density.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Urine Parameter: Specific Gravity-Part 1 Baseline; n=18, 18	—	1.0120 Ratio Standard Deviation 0.00915	1.0120 Ratio Standard Deviation 0.00915
Absolute Values for Urine Parameter: Specific Gravity-Part 1 Day 2; n=18, 18	—	1.0152 Ratio Standard Deviation 0.00685	1.0158 Ratio Standard Deviation 0.00584
Absolute Values for Urine Parameter: Specific Gravity-Part 1 Day 5; n=9, 9	—	1.0201 Ratio Standard Deviation 0.00664	1.0161 Ratio Standard Deviation 0.00434

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine urobilinogen.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Urine Parameter: Urobilinogen-Part 1 Baseline; n=18, 18	—	4.1384 Micromoles per liter Standard Deviation 3.19235	4.1384 Micromoles per liter Standard Deviation 3.19235
Absolute Values for Urine Parameter: Urobilinogen-Part 1 Day 2; n=18, 18	—	3.3860 Micromoles per liter Standard Deviation 0.00000	4.1384 Micromoles per liter Standard Deviation 3.19235
Absolute Values for Urine Parameter: Urobilinogen-Part 1 Day 5; n=9, 9	—	3.3860 Micromoles per liter Standard Deviation 0.00000	3.3860 Micromoles per liter Standard Deviation 0.00000

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0).

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Urine Parameter: Potential of Hydrogen (pH)-Part 1 Baseline; n=18, 18	—	6.03 pH Standard Deviation 0.696	6.03 pH Standard Deviation 0.696
Absolute Values for Urine Parameter: Potential of Hydrogen (pH)-Part 1 Day 2; n=18, 18	—	6.14 pH Standard Deviation 0.682	6.25 pH Standard Deviation 0.600
Absolute Values for Urine Parameter: Potential of Hydrogen (pH)-Part 1 Day 5; n=9, 9	—	5.72 pH Standard Deviation 0.441	5.89 pH Standard Deviation 0.697

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine, indicated as ratio of urine density to water density.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Urine Parameter: Specific Gravity-Part 2 Baseline; n=20, 19, 21	1.0080 Ratio Standard Deviation 0.00735	1.0080 Ratio Standard Deviation 0.00735	1.0080 Ratio Standard Deviation 0.00735
Absolute Values for Urine Parameter: Specific Gravity-Part 2 Day 2; n=20, 19, 21	1.0163 Ratio Standard Deviation 0.00419	1.0166 Ratio Standard Deviation 0.00675	1.0151 Ratio Standard Deviation 0.00552
Absolute Values for Urine Parameter: Specific Gravity-Part 2 Day 5; n=7, 5, 7	1.0171 Ratio Standard Deviation 0.00999	1.0180 Ratio Standard Deviation 0.00632	1.0248 Ratio Standard Deviation 0.00526

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine urobilinogen.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Urine Parameter: Urobilinogen-Part 2 Baseline; n=20, 19, 21	4.6759 Micromoles per liter Standard Deviation 4.03794	4.6759 Micromoles per liter Standard Deviation 4.03794	4.6759 Micromoles per liter Standard Deviation 4.03794
Absolute Values for Urine Parameter: Urobilinogen-Part 2 Day 2; n=20, 19, 21	3.3860 Micromoles per liter Standard Deviation 0.00000	4.0632 Micromoles per liter Standard Deviation 3.02853	3.3860 Micromoles per liter Standard Deviation 0.00000
Absolute Values for Urine Parameter: Urobilinogen-Part 2 Day 5; n=7, 5, 7	5.3209 Micromoles per liter Standard Deviation 5.11915	3.3860 Micromoles per liter Standard Deviation 0.00000	6.0948 Micromoles per liter Standard Deviation 6.05706

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0).

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Urine Parameter: pH-Part 2 Baseline; n=20, 19, 21	6.36 pH Standard Deviation 0.727	6.36 pH Standard Deviation 0.727	6.36 pH Standard Deviation 0.727
Absolute Values for Urine Parameter: pH-Part 2 Day 2; n=20, 19, 21	6.10 pH Standard Deviation 0.718	6.15 pH Standard Deviation 0.690	6.08 pH Standard Deviation 0.584
Absolute Values for Urine Parameter: pH-Part 2 Day 5; n=7, 5, 7	6.21 pH Standard Deviation 0.393	5.86 pH Standard Deviation 0.627	5.60 pH Standard Deviation 0.418

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine, indicated as ratio of urine density to water density. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Urine Parameter: Specific Gravity-Part 1 Day 2; n=18, 18	—	0.0032 Ratio Standard Deviation 0.01242	0.0038 Ratio Standard Deviation 0.01043
Change From Baseline in Urine Parameter: Specific Gravity-Part 1 Day 5; n=9, 9	—	0.0088 Ratio Standard Deviation 0.01210	0.0034 Ratio Standard Deviation 0.01180

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Urine Parameter: Urobilinogen-Part 1 Day 2; n=18, 18	—	-0.7524 Micromoles per liter Standard Deviation 3.19235	0.0000 Micromoles per liter Standard Deviation 4.64555
Change From Baseline in Urine Parameter: Urobilinogen-Part 1 Day 5; n=9, 9	—	0.0000 Micromoles per liter Standard Deviation 0.00000	-1.5049 Micromoles per liter Standard Deviation 4.51467

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Urine Parameter: pH-Part 1 Day 2; n=18, 18	—	0.11 pH Standard Deviation 1.008	0.22 pH Standard Deviation 0.974
Change From Baseline in Urine Parameter: pH-Part 1 Day 5; n=9, 9	—	-0.17 pH Standard Deviation 0.559	-0.28 pH Standard Deviation 1.121

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine, indicated as ratio of urine density to water density. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Urine Parameter: Specific Gravity-Part 2 Day 2; n=20, 19, 21	0.0083 Ratio Standard Deviation 0.00728	0.0084 Ratio Standard Deviation 0.00942	0.0066 Ratio Standard Deviation 0.00718
Change From Baseline in Urine Parameter: Specific Gravity-Part 2 Day 5; n=7, 5, 7	0.0091 Ratio Standard Deviation 0.00956	0.0109 Ratio Standard Deviation 0.00825	0.0140 Ratio Standard Deviation 0.01142

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Urine Parameter: Urobilinogen-Part 2 Day 2; n=20, 19, 21	-1.2899 Micromoles per liter Standard Deviation 4.07394	-0.6772 Micromoles per liter Standard Deviation 5.33680	-1.4275 Micromoles per liter Standard Deviation 4.27045
Change From Baseline in Urine Parameter: Urobilinogen-Part 2 Day 5; n=7, 5, 7	1.9349 Micromoles per liter Standard Deviation 5.11915	0.0000 Micromoles per liter Standard Deviation 0.00000	-2.7088 Micromoles per liter Standard Deviation 6.05706

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Urine Parameter: pH-Part 2 Day 2; n=20, 19, 21	-0.26 pH Standard Deviation 0.664	-0.18 pH Standard Deviation 0.799	-0.18 pH Standard Deviation 0.730
Change From Baseline in Urine Parameter: pH-Part 2 Day 5; n=7, 5, 7	0.07 pH Standard Deviation 0.450	-0.43 pH Standard Deviation 0.787	-0.80 pH Standard Deviation 0.837

SECONDARY outcome

Timeframe: Day 2 and Day 5

Population: Safety Population

Urine samples were collected at indicated time points for the assessment of following urine parameters: bilirubin, glucose, ketones, nitrite, leukocyte esterase, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner, and results can be read as Trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Only parameters and time points with abnormal results have been presented.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Leukocyte esterase, Day 2, Trace	—	0 Participants	1 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Leukocyte esterase, Day 2, 1+	—	1 Participants	0 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Leukocyte esterase, Day 5, Trace	—	0 Participants	1 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Leukocyte esterase, Day 5, 1+	—	0 Participants	1 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Occult blood, Day 2, Trace	—	1 Participants	1 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Occult blood, Day 2, 1+	—	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 2 and Day 5

Population: Safety Population

Urine samples were collected at indicated time points for the assessment of following urine parameters: bilirubin, glucose, ketones, nitrite, leukocyte esterase, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner, and results can be read as Trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Only parameters and time points with abnormal results have been presented.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Ketones; Day 5; Trace	0 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Ketones; Day 5; 2+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Leukocyte esterase; Day 2; 1+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Occult blood; Day 2; Trace	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Occult blood; Day 2; 2+	0 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Occult blood; Day 2; 3+	2 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Day 1 (2 hours and 4 hours) and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. ECGs were obtained using an ECG machine that automatically measured PR, QRS, QT, and QTcF intervals.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 PR interval, Baseline; n=18, 18	—	164.1 Milliseconds Standard Deviation 22.81	162.3 Milliseconds Standard Deviation 20.76
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 PR interval, Day 1 (2 hours); n=18, 18	—	166.3 Milliseconds Standard Deviation 21.55	158.7 Milliseconds Standard Deviation 19.95
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 PR interval, Day 1 (4 hours); n=18, 18	—	160.6 Milliseconds Standard Deviation 20.94	158.9 Milliseconds Standard Deviation 19.19
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 PR interval, Day 5; n=9, 9	—	161.8 Milliseconds Standard Deviation 11.68	169.3 Milliseconds Standard Deviation 26.14
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QRS duration, Baseline; n=18, 18	—	93.4 Milliseconds Standard Deviation 9.30	92.5 Milliseconds Standard Deviation 8.09
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QRS duration, Day 1 (2 hours); n=18, 18	—	91.9 Milliseconds Standard Deviation 8.76	92.6 Milliseconds Standard Deviation 9.00
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QRS duration, Day 1 (4 hours); n=18, 18	—	94.1 Milliseconds Standard Deviation 8.88	93.8 Milliseconds Standard Deviation 9.90
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QRS duration, Day 5; n=9, 9	—	94.3 Milliseconds Standard Deviation 11.65	92.4 Milliseconds Standard Deviation 8.25
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QT interval, Baseline; n=18, 18	—	395.1 Milliseconds Standard Deviation 14.22	394.4 Milliseconds Standard Deviation 24.04
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QT interval, Day 1 (2 hours); n=18, 18	—	383.3 Milliseconds Standard Deviation 13.71	383.6 Milliseconds Standard Deviation 24.11
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QT interval, Day 1 (4 hours); n=18, 18	—	404.8 Milliseconds Standard Deviation 16.36	402.0 Milliseconds Standard Deviation 27.67
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QT interval, Day 5; n=9, 9	—	393.4 Milliseconds Standard Deviation 16.38	402.7 Milliseconds Standard Deviation 18.71
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QTcF interval, Baseline; n=18, 18	—	399.4 Milliseconds Standard Deviation 9.76	401.9 Milliseconds Standard Deviation 15.01
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QTcF interval, Day 1 (2 hours); n=18, 18	—	389.5 Milliseconds Standard Deviation 12.11	392.8 Milliseconds Standard Deviation 15.09
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QTcF interval, Day 1 (4 hours); n=18, 18	—	398.7 Milliseconds Standard Deviation 11.13	402.6 Milliseconds Standard Deviation 19.46
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QTcF interval, Day 5; n=9, 9	—	400.8 Milliseconds Standard Deviation 13.34	399.4 Milliseconds Standard Deviation 11.98

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Day 1 (2 hours and 4 hours) and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. ECGs were obtained using an ECG machine that automatically measured PR, QRS, QT, and QTcF intervals.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Baseline; n=20, 19, 21	166.8 Milliseconds Standard Deviation 17.01	166.4 Milliseconds Standard Deviation 16.48	166.2 Milliseconds Standard Deviation 15.40
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 1 (2 hours); n=20, 19, 21	161.7 Milliseconds Standard Deviation 16.82	163.9 Milliseconds Standard Deviation 18.45	166.8 Milliseconds Standard Deviation 15.23
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 1 (4 hours); n=20, 19, 21	162.6 Milliseconds Standard Deviation 13.99	165.2 Milliseconds Standard Deviation 17.74	165.7 Milliseconds Standard Deviation 15.29
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 5; n=7, 5, 7	163.1 Milliseconds Standard Deviation 12.36	173.4 Milliseconds Standard Deviation 19.16	171.6 Milliseconds Standard Deviation 14.57
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Baseline; n=20, 19, 21	90.1 Milliseconds Standard Deviation 10.42	92.1 Milliseconds Standard Deviation 9.76	91.7 Milliseconds Standard Deviation 9.02
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 1 (2 hours); n=20, 19, 21	89.7 Milliseconds Standard Deviation 9.86	88.9 Milliseconds Standard Deviation 9.68	92.6 Milliseconds Standard Deviation 9.82
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 1 (4 hours); n=20, 19, 21	90.3 Milliseconds Standard Deviation 8.69	91.1 Milliseconds Standard Deviation 10.63	93.2 Milliseconds Standard Deviation 8.45
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 5; n=7, 5, 7	88.7 Milliseconds Standard Deviation 5.28	101.1 Milliseconds Standard Deviation 7.10	85.8 Milliseconds Standard Deviation 8.07
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Baseline; n=20, 19, 21	389.7 Milliseconds Standard Deviation 26.09	391.8 Milliseconds Standard Deviation 28.22	388.5 Milliseconds Standard Deviation 24.78
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 1 (2 hours); n=20, 19, 21	376.2 Milliseconds Standard Deviation 22.54	379.7 Milliseconds Standard Deviation 25.70	399.2 Milliseconds Standard Deviation 22.43
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 1 (4 hours); n=20, 19, 21	389.1 Milliseconds Standard Deviation 25.95	401.0 Milliseconds Standard Deviation 25.84	406.9 Milliseconds Standard Deviation 22.25
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 5; n=7, 5, 7	378.9 Milliseconds Standard Deviation 25.15	401.7 Milliseconds Standard Deviation 33.29	391.0 Milliseconds Standard Deviation 10.27
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Baseline; n=20, 19, 21	391.9 Milliseconds Standard Deviation 21.63	395.3 Milliseconds Standard Deviation 21.06	392.4 Milliseconds Standard Deviation 19.45
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 1 (2 hours); n=20, 19, 21	388.3 Milliseconds Standard Deviation 18.91	384.0 Milliseconds Standard Deviation 19.91	391.7 Milliseconds Standard Deviation 21.77
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 1 (4 hours); n=20, 19, 21	393.3 Milliseconds Standard Deviation 20.78	396.8 Milliseconds Standard Deviation 21.90	395.5 Milliseconds Standard Deviation 20.75
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 5; n=7, 5, 7	388.1 Milliseconds Standard Deviation 22.81	391.9 Milliseconds Standard Deviation 30.45	402.4 Milliseconds Standard Deviation 7.70

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Day 1 (2 hours and 4 hours) and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. ECGs were obtained using an ECG machine that automatically measured PR, QRS, QT, and QTcF intervals. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 PR interval, Day 1 (2 hours); n=18, 18	—	2.2 Milliseconds Standard Deviation 8.35	-3.6 Milliseconds Standard Deviation 10.01
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 PR interval, Day 1 (4 hours); n=18, 18	—	-3.6 Milliseconds Standard Deviation 11.61	-3.3 Milliseconds Standard Deviation 10.85
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 PR interval, Day 5; n=9, 9	—	-0.9 Milliseconds Standard Deviation 13.72	3.2 Milliseconds Standard Deviation 8.35
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QRS duration, Day 1 (2 hours); n=18, 18	—	-1.5 Milliseconds Standard Deviation 2.81	0.1 Milliseconds Standard Deviation 6.06
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QRS duration, Day 1 (4 hours); n=18, 18	—	0.7 Milliseconds Standard Deviation 3.63	1.3 Milliseconds Standard Deviation 4.92
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QRS duration, Day 5; n=9, 9	—	-0.3 Milliseconds Standard Deviation 3.74	0.8 Milliseconds Standard Deviation 3.46
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QT interval, Day 1 (2 hours); n=18, 18	—	-11.8 Milliseconds Standard Deviation 10.70	-10.8 Milliseconds Standard Deviation 11.18
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QT interval, Day 1 (4 hours); n=18, 18	—	9.7 Milliseconds Standard Deviation 13.99	7.6 Milliseconds Standard Deviation 16.85
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QT interval, Day 5; n=9, 9	—	-1.3 Milliseconds Standard Deviation 10.00	5.0 Milliseconds Standard Deviation 26.51
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QTcF interval, Day 1 (2 hours); n=18, 18	—	-9.9 Milliseconds Standard Deviation 6.49	-9.1 Milliseconds Standard Deviation 9.16
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QTcF interval, Day 1 (4 hours); n=18, 18	—	-0.7 Milliseconds Standard Deviation 7.71	0.7 Milliseconds Standard Deviation 9.23
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QTcF interval, Day 5; n=9, 9	—	-0.7 Milliseconds Standard Deviation 7.19	3.9 Milliseconds Standard Deviation 7.93

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Day 1 (2 hours and 4 hours) and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. ECGs were obtained using an ECG machine that automatically measured PR, QRS, QT, and QTcF intervals. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 1 (4 hours); n=20, 19, 21	-0.6 Milliseconds Standard Deviation 14.14	9.2 Milliseconds Standard Deviation 18.08	18.4 Milliseconds Standard Deviation 12.90
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 5; n=7, 5, 7	-2.9 Milliseconds Standard Deviation 7.95	-2.1 Milliseconds Standard Deviation 10.67	-12.4 Milliseconds Standard Deviation 13.28
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 1 (2 hours); n=20, 19, 21	-3.5 Milliseconds Standard Deviation 8.70	-11.3 Milliseconds Standard Deviation 7.04	-0.6 Milliseconds Standard Deviation 7.33
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 1 (4 hours); n=20, 19, 21	1.4 Milliseconds Standard Deviation 7.64	1.6 Milliseconds Standard Deviation 7.50	3.1 Milliseconds Standard Deviation 7.75
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 5; n=7, 5, 7	1.7 Milliseconds Standard Deviation 8.30	-0.4 Milliseconds Standard Deviation 9.34	-1.4 Milliseconds Standard Deviation 3.91
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 1 (2 hours); n=20, 19, 21	-5.0 Milliseconds Standard Deviation 8.29	-2.5 Milliseconds Standard Deviation 7.02	0.7 Milliseconds Standard Deviation 7.90
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 1 (4 hours); n=20, 19, 21	-4.2 Milliseconds Standard Deviation 6.79	-1.2 Milliseconds Standard Deviation 8.47	-0.4 Milliseconds Standard Deviation 11.52
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 5; n=7, 5, 7	-2.7 Milliseconds Standard Deviation 16.42	2.0 Milliseconds Standard Deviation 4.08	1.6 Milliseconds Standard Deviation 11.26
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 1 (2 hours); n=20, 19, 21	-0.5 Milliseconds Standard Deviation 3.03	-3.2 Milliseconds Standard Deviation 3.44	0.9 Milliseconds Standard Deviation 3.90
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 1 (4 hours); n=20, 19, 21	0.2 Milliseconds Standard Deviation 4.12	-1.0 Milliseconds Standard Deviation 4.18	1.5 Milliseconds Standard Deviation 4.45
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 5; n=7, 5, 7	0.4 Milliseconds Standard Deviation 2.88	0.4 Milliseconds Standard Deviation 3.21	-0.4 Milliseconds Standard Deviation 3.13
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 1 (2 hours); n=20, 19, 21	-13.4 Milliseconds Standard Deviation 15.31	-12.1 Milliseconds Standard Deviation 18.05	10.6 Milliseconds Standard Deviation 12.36

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Blood pressure was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Baseline	—	118.3 Millimeters of mercury Standard Deviation 9.73	117.4 Millimeters of mercury Standard Deviation 12.26
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Day 2	—	113.8 Millimeters of mercury Standard Deviation 10.32	115.1 Millimeters of mercury Standard Deviation 11.94
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Day 3	—	113.6 Millimeters of mercury Standard Deviation 12.13	113.3 Millimeters of mercury Standard Deviation 9.71
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Day 4	—	112.2 Millimeters of mercury Standard Deviation 11.11	113.9 Millimeters of mercury Standard Deviation 10.57
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Day 5	—	112.2 Millimeters of mercury Standard Deviation 9.62	113.8 Millimeters of mercury Standard Deviation 8.91
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Baseline	—	72.1 Millimeters of mercury Standard Deviation 8.35	73.4 Millimeters of mercury Standard Deviation 8.51
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Day 2	—	70.1 Millimeters of mercury Standard Deviation 7.06	71.3 Millimeters of mercury Standard Deviation 10.56
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Day 3	—	70.4 Millimeters of mercury Standard Deviation 7.72	69.1 Millimeters of mercury Standard Deviation 8.46
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Day 4	—	70.2 Millimeters of mercury Standard Deviation 6.98	68.7 Millimeters of mercury Standard Deviation 6.77
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Day 5	—	70.1 Millimeters of mercury Standard Deviation 7.68	68.9 Millimeters of mercury Standard Deviation 5.76

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Pulse rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Vital Sign: Pulse Rate-Part 1 Baseline	—	65.7 Beats per minute Standard Deviation 5.27	66.2 Beats per minute Standard Deviation 10.00
Absolute Values for Vital Sign: Pulse Rate-Part 1 Day 2	—	66.7 Beats per minute Standard Deviation 7.02	68.4 Beats per minute Standard Deviation 8.71
Absolute Values for Vital Sign: Pulse Rate-Part 1 Day 3	—	67.4 Beats per minute Standard Deviation 7.79	68.6 Beats per minute Standard Deviation 9.58
Absolute Values for Vital Sign: Pulse Rate-Part 1 Day 4	—	67.4 Beats per minute Standard Deviation 7.89	65.6 Beats per minute Standard Deviation 9.37
Absolute Values for Vital Sign: Pulse Rate-Part 1 Day 5	—	64.4 Beats per minute Standard Deviation 6.97	66.9 Beats per minute Standard Deviation 8.39

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Baseline; n=18, 18	—	14.0 Breaths per minute Standard Deviation 2.66	14.9 Breaths per minute Standard Deviation 1.71
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Day 2; n=17, 17	—	13.1 Breaths per minute Standard Deviation 2.56	13.9 Breaths per minute Standard Deviation 2.69
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Day 3; n=17, 18	—	14.7 Breaths per minute Standard Deviation 2.11	15.2 Breaths per minute Standard Deviation 2.49
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Day 4; n=18, 18	—	13.9 Breaths per minute Standard Deviation 2.87	14.7 Breaths per minute Standard Deviation 3.07
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Day 5; n=18, 18	—	14.0 Breaths per minute Standard Deviation 2.47	14.1 Breaths per minute Standard Deviation 1.75

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Vital Sign: Temperature-Part 1 Baseline	—	36.24 Degrees Celsius Standard Deviation 0.393	36.37 Degrees Celsius Standard Deviation 0.361
Absolute Values for Vital Sign: Temperature-Part 1 Day 2	—	36.22 Degrees Celsius Standard Deviation 0.426	36.39 Degrees Celsius Standard Deviation 0.407
Absolute Values for Vital Sign: Temperature-Part 1 Day 3	—	36.33 Degrees Celsius Standard Deviation 0.420	36.22 Degrees Celsius Standard Deviation 0.383
Absolute Values for Vital Sign: Temperature-Part 1 Day 4	—	36.38 Degrees Celsius Standard Deviation 0.402	36.35 Degrees Celsius Standard Deviation 0.385
Absolute Values for Vital Sign: Temperature-Part 1 Day 5	—	36.21 Degrees Celsius Standard Deviation 0.555	36.27 Degrees Celsius Standard Deviation 0.324

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Blood pressure was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Baseline	117.4 Millimeters of mercury Standard Deviation 13.01	120.8 Millimeters of mercury Standard Deviation 17.53	115.2 Millimeters of mercury Standard Deviation 11.46
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Day 2	115.7 Millimeters of mercury Standard Deviation 11.73	117.4 Millimeters of mercury Standard Deviation 11.84	116.6 Millimeters of mercury Standard Deviation 11.32
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Day 3	116.6 Millimeters of mercury Standard Deviation 12.36	115.8 Millimeters of mercury Standard Deviation 10.63	117.2 Millimeters of mercury Standard Deviation 11.47
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Day 4	118.0 Millimeters of mercury Standard Deviation 16.87	119.0 Millimeters of mercury Standard Deviation 12.75	115.4 Millimeters of mercury Standard Deviation 11.14
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Day 5	118.0 Millimeters of mercury Standard Deviation 13.18	118.2 Millimeters of mercury Standard Deviation 12.92	115.8 Millimeters of mercury Standard Deviation 12.76
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Baseline	71.8 Millimeters of mercury Standard Deviation 7.51	74.8 Millimeters of mercury Standard Deviation 10.44	71.4 Millimeters of mercury Standard Deviation 9.62
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Day 2	71.1 Millimeters of mercury Standard Deviation 7.48	72.5 Millimeters of mercury Standard Deviation 9.26	74.2 Millimeters of mercury Standard Deviation 9.83
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Day 3	72.4 Millimeters of mercury Standard Deviation 7.53	72.9 Millimeters of mercury Standard Deviation 7.57	72.9 Millimeters of mercury Standard Deviation 9.24
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Day 4	70.5 Millimeters of mercury Standard Deviation 9.26	71.9 Millimeters of mercury Standard Deviation 6.94	73.5 Millimeters of mercury Standard Deviation 8.32
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Day 5	68.7 Millimeters of mercury Standard Deviation 9.18	72.0 Millimeters of mercury Standard Deviation 8.61	72.3 Millimeters of mercury Standard Deviation 7.64

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Pulse rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Vital Sign: Pulse Rate-Part 2 Baseline	63.8 Beats per minute Standard Deviation 7.85	65.4 Beats per minute Standard Deviation 12.47	64.1 Beats per minute Standard Deviation 7.70
Absolute Values for Vital Sign: Pulse Rate-Part 2 Day 2	64.1 Beats per minute Standard Deviation 7.94	66.9 Beats per minute Standard Deviation 12.76	64.0 Beats per minute Standard Deviation 10.66
Absolute Values for Vital Sign: Pulse Rate-Part 2 Day 3	67.4 Beats per minute Standard Deviation 11.04	66.7 Beats per minute Standard Deviation 11.28	64.9 Beats per minute Standard Deviation 14.16
Absolute Values for Vital Sign: Pulse Rate-Part 2 Day 4	72.6 Beats per minute Standard Deviation 12.36	70.8 Beats per minute Standard Deviation 12.90	68.2 Beats per minute Standard Deviation 11.25
Absolute Values for Vital Sign: Pulse Rate-Part 2 Day 5	69.6 Beats per minute Standard Deviation 13.99	67.6 Beats per minute Standard Deviation 11.19	69.1 Beats per minute Standard Deviation 9.11

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Baseline	13.8 Breaths per minute Standard Deviation 2.27	14.8 Breaths per minute Standard Deviation 1.20	15.3 Breaths per minute Standard Deviation 2.02
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Day 2	14.2 Breaths per minute Standard Deviation 2.36	14.3 Breaths per minute Standard Deviation 2.27	15.4 Breaths per minute Standard Deviation 1.64
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Day 3	14.2 Breaths per minute Standard Deviation 2.18	15.0 Breaths per minute Standard Deviation 2.00	14.5 Breaths per minute Standard Deviation 1.98
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Day 4	14.3 Breaths per minute Standard Deviation 2.22	14.9 Breaths per minute Standard Deviation 2.38	14.0 Breaths per minute Standard Deviation 3.06
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Day 5	14.6 Breaths per minute Standard Deviation 1.80	13.7 Breaths per minute Standard Deviation 1.63	14.5 Breaths per minute Standard Deviation 1.61

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Vital Sign: Temperature-Part 2 Baseline	36.37 Degrees Celsius Standard Deviation 0.483	36.24 Degrees Celsius Standard Deviation 0.421	36.50 Degrees Celsius Standard Deviation 0.298
Absolute Values for Vital Sign: Temperature-Part 2 Day 2	36.27 Degrees Celsius Standard Deviation 0.508	36.29 Degrees Celsius Standard Deviation 0.476	36.40 Degrees Celsius Standard Deviation 0.406
Absolute Values for Vital Sign: Temperature-Part 2 Day 3	36.29 Degrees Celsius Standard Deviation 0.419	36.33 Degrees Celsius Standard Deviation 0.351	36.37 Degrees Celsius Standard Deviation 0.425
Absolute Values for Vital Sign: Temperature-Part 2 Day 4	36.38 Degrees Celsius Standard Deviation 0.495	36.37 Degrees Celsius Standard Deviation 0.404	36.37 Degrees Celsius Standard Deviation 0.378
Absolute Values for Vital Sign: Temperature-Part 2 Day 5	36.51 Degrees Celsius Standard Deviation 0.459	36.34 Degrees Celsius Standard Deviation 0.345	36.49 Degrees Celsius Standard Deviation 0.375

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Blood pressure was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Vital Signs: SBP and DBP-Part 1 SBP; Day 2	—	-4.5 Millimeters of mercury Standard Deviation 7.52	-2.3 Millimeters of mercury Standard Deviation 7.22
Change From Baseline in Vital Signs: SBP and DBP-Part 1 SBP; Day 3	—	-4.7 Millimeters of mercury Standard Deviation 9.63	-4.1 Millimeters of mercury Standard Deviation 9.63
Change From Baseline in Vital Signs: SBP and DBP-Part 1 SBP; Day 4	—	-6.1 Millimeters of mercury Standard Deviation 7.45	-3.4 Millimeters of mercury Standard Deviation 10.18
Change From Baseline in Vital Signs: SBP and DBP-Part 1 SBP; Day 5	—	-6.1 Millimeters of mercury Standard Deviation 7.49	-3.6 Millimeters of mercury Standard Deviation 11.37
Change From Baseline in Vital Signs: SBP and DBP-Part 1 DBP; Day 2	—	-2.0 Millimeters of mercury Standard Deviation 6.82	-2.2 Millimeters of mercury Standard Deviation 5.78
Change From Baseline in Vital Signs: SBP and DBP-Part 1 DBP; Day 3	—	-1.7 Millimeters of mercury Standard Deviation 7.46	-4.3 Millimeters of mercury Standard Deviation 4.80
Change From Baseline in Vital Signs: SBP and DBP-Part 1 DBP; Day 4	—	-1.9 Millimeters of mercury Standard Deviation 6.98	-4.7 Millimeters of mercury Standard Deviation 6.99
Change From Baseline in Vital Signs: SBP and DBP-Part 1 DBP; Day 5	—	-2.1 Millimeters of mercury Standard Deviation 7.46	-4.6 Millimeters of mercury Standard Deviation 7.17

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Pulse rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Vital Sign: Pulse Rate-Part 1 Day 2	—	1.1 Beats per minute Standard Deviation 5.76	2.2 Beats per minute Standard Deviation 7.50
Change From Baseline in Vital Sign: Pulse Rate-Part 1 Day 3	—	1.8 Beats per minute Standard Deviation 8.20	2.4 Beats per minute Standard Deviation 7.41
Change From Baseline in Vital Sign: Pulse Rate-Part 1 Day 4	—	1.7 Beats per minute Standard Deviation 6.93	-0.6 Beats per minute Standard Deviation 7.88
Change From Baseline in Vital Sign: Pulse Rate-Part 1 Day 5	—	-1.3 Beats per minute Standard Deviation 5.46	0.8 Beats per minute Standard Deviation 10.70

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the latest predose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Vital Sign: Respiratory Rate-Part 1 Day 2; n=17, 17	—	-1.1 Breaths per minute Standard Deviation 3.47	-0.8 Breaths per minute Standard Deviation 3.00
Change From Baseline in Vital Sign: Respiratory Rate-Part 1 Day 3; n=17, 18	—	0.6 Breaths per minute Standard Deviation 2.62	0.3 Breaths per minute Standard Deviation 3.58
Change From Baseline in Vital Sign: Respiratory Rate-Part 1 Day 4; n=18, 18	—	-0.1 Breaths per minute Standard Deviation 2.78	-0.2 Breaths per minute Standard Deviation 3.35
Change From Baseline in Vital Sign: Respiratory Rate-Part 1 Day 5; n=18, 18	—	0.0 Breaths per minute Standard Deviation 2.74	-0.8 Breaths per minute Standard Deviation 2.76

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the latest predose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Vital Sign: Temperature-Part 1 Day 2	—	-0.03 Degrees Celsius Standard Deviation 0.329	0.02 Degrees Celsius Standard Deviation 0.472
Change From Baseline in Vital Sign: Temperature-Part 1 Day 3	—	0.09 Degrees Celsius Standard Deviation 0.442	-0.15 Degrees Celsius Standard Deviation 0.444
Change From Baseline in Vital Sign: Temperature-Part 1 Day 4	—	0.13 Degrees Celsius Standard Deviation 0.452	-0.02 Degrees Celsius Standard Deviation 0.458
Change From Baseline in Vital Sign: Temperature-Part 1 Day 5	—	-0.04 Degrees Celsius Standard Deviation 0.501	-0.11 Degrees Celsius Standard Deviation 0.330

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Blood pressure was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Vital Signs: SBP and DBP-Part 2 SBP, Day 2	-1.7 Millimeters of mercury Standard Deviation 7.65	-3.5 Millimeters of mercury Standard Deviation 10.50	1.5 Millimeters of mercury Standard Deviation 6.59
Change From Baseline in Vital Signs: SBP and DBP-Part 2 SBP, Day 3	-0.9 Millimeters of mercury Standard Deviation 9.11	-5.1 Millimeters of mercury Standard Deviation 12.99	2.1 Millimeters of mercury Standard Deviation 7.74
Change From Baseline in Vital Signs: SBP and DBP-Part 2 SBP, Day 4	0.6 Millimeters of mercury Standard Deviation 9.95	-1.9 Millimeters of mercury Standard Deviation 12.28	0.3 Millimeters of mercury Standard Deviation 6.10
Change From Baseline in Vital Signs: SBP and DBP-Part 2 SBP, Day 5	0.6 Millimeters of mercury Standard Deviation 7.71	-2.6 Millimeters of mercury Standard Deviation 11.23	0.7 Millimeters of mercury Standard Deviation 8.28
Change From Baseline in Vital Signs: SBP and DBP-Part 2 DBP, Day 2	-0.7 Millimeters of mercury Standard Deviation 4.90	-2.4 Millimeters of mercury Standard Deviation 6.10	2.8 Millimeters of mercury Standard Deviation 5.07
Change From Baseline in Vital Signs: SBP and DBP-Part 2 DBP, Day 3	0.6 Millimeters of mercury Standard Deviation 4.95	-1.9 Millimeters of mercury Standard Deviation 6.40	1.5 Millimeters of mercury Standard Deviation 7.83
Change From Baseline in Vital Signs: SBP and DBP-Part 2 DBP, Day 4	-1.3 Millimeters of mercury Standard Deviation 6.63	-2.9 Millimeters of mercury Standard Deviation 8.53	2.2 Millimeters of mercury Standard Deviation 6.27
Change From Baseline in Vital Signs: SBP and DBP-Part 2 DBP, Day 5	-3.0 Millimeters of mercury Standard Deviation 7.92	-2.9 Millimeters of mercury Standard Deviation 6.19	0.9 Millimeters of mercury Standard Deviation 6.99

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Pulse rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Vital Sign: Pulse Rate-Part 2 Day 2	0.3 Beats per minute Standard Deviation 4.72	1.5 Beats per minute Standard Deviation 7.39	-0.1 Beats per minute Standard Deviation 8.02
Change From Baseline in Vital Sign: Pulse Rate-Part 2 Day 3	3.7 Beats per minute Standard Deviation 6.59	1.3 Beats per minute Standard Deviation 9.69	0.9 Beats per minute Standard Deviation 13.16
Change From Baseline in Vital Sign: Pulse Rate-Part 2 Day 4	8.9 Beats per minute Standard Deviation 8.21	5.4 Beats per minute Standard Deviation 10.17	4.1 Beats per minute Standard Deviation 9.64
Change From Baseline in Vital Sign: Pulse Rate-Part 2 Day 5	5.9 Beats per minute Standard Deviation 8.43	2.2 Beats per minute Standard Deviation 6.39	5.0 Beats per minute Standard Deviation 8.37

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the latest predose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Vital Sign: Respiratory Rate-Part 2 Day 2	0.4 Breaths per minute Standard Deviation 2.58	-0.5 Breaths per minute Standard Deviation 2.24	0.1 Breaths per minute Standard Deviation 2.62
Change From Baseline in Vital Sign: Respiratory Rate-Part 2 Day 3	0.4 Breaths per minute Standard Deviation 3.61	0.2 Breaths per minute Standard Deviation 2.42	-0.7 Breaths per minute Standard Deviation 2.42
Change From Baseline in Vital Sign: Respiratory Rate-Part 2 Day 4	0.5 Breaths per minute Standard Deviation 2.27	0.1 Breaths per minute Standard Deviation 2.20	-1.3 Breaths per minute Standard Deviation 3.72
Change From Baseline in Vital Sign: Respiratory Rate-Part 2 Day 5	0.8 Breaths per minute Standard Deviation 2.86	-1.1 Breaths per minute Standard Deviation 1.77	-0.7 Breaths per minute Standard Deviation 1.91

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the latest predose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Vital Sign: Temperature-Part 2 Day 2	-0.10 Degrees Celsius Standard Deviation 0.390	0.05 Degrees Celsius Standard Deviation 0.477	-0.10 Degrees Celsius Standard Deviation 0.325
Change From Baseline in Vital Sign: Temperature-Part 2 Day 3	-0.08 Degrees Celsius Standard Deviation 0.453	0.09 Degrees Celsius Standard Deviation 0.302	-0.13 Degrees Celsius Standard Deviation 0.245
Change From Baseline in Vital Sign: Temperature-Part 2 Day 4	0.01 Degrees Celsius Standard Deviation 0.399	0.13 Degrees Celsius Standard Deviation 0.490	-0.13 Degrees Celsius Standard Deviation 0.268
Change From Baseline in Vital Sign: Temperature-Part 2 Day 5	0.15 Degrees Celsius Standard Deviation 0.437	0.10 Degrees Celsius Standard Deviation 0.426	-0.01 Degrees Celsius Standard Deviation 0.375

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Lag Time for Absorption (Tlag) for GSK3640254-Part 1	—	0.528 Hours Standard Deviation 0.7568	0.139 Hours Standard Deviation 0.4132

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Apparent Terminal Phase Half-life (t1/2) for GSK3640254-Part 1	—	26.247 Hours Geometric Coefficient of Variation 17.6	26.185 Hours Geometric Coefficient of Variation 17.2

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Apparent Oral Clearance (CL/F) for GSK3640254-Part 1	—	5.413 Liters per hour Geometric Coefficient of Variation 42.7	5.423 Liters per hour Geometric Coefficient of Variation 40.3

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Apparent Volume of Distribution (Vz/F) for GSK3640254-Part 1	—	205.0 Liters Geometric Coefficient of Variation 40.0	204.9 Liters Geometric Coefficient of Variation 43.0

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Concentration Population comprised of all participants who underwent plasma PK sampling and had evaluable PK assay results.

Blood samples were collected at indicated time points for PK analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Plasma Concentration of GSK3640254-Part 1 pre-dose	—	1.910 Nanograms per milliliter Interval 0.0 to 44.1	1.580 Nanograms per milliliter Interval 0.0 to 31.5
Plasma Concentration of GSK3640254-Part 1 1 hour	—	6.795 Nanograms per milliliter Interval 0.0 to 80.8	81.90 Nanograms per milliliter Interval 0.0 to 842.0
Plasma Concentration of GSK3640254-Part 1 1.5 hours	—	26.40 Nanograms per milliliter Interval 0.0 to 421.0	291.0 Nanograms per milliliter Interval 0.0 to 1650.0
Plasma Concentration of GSK3640254-Part 1 2 hours	—	104.5 Nanograms per milliliter Interval 0.0 to 991.0	502.5 Nanograms per milliliter Interval 28.1 to 2160.0
Plasma Concentration of GSK3640254-Part 1 2.5 hours	—	342.5 Nanograms per milliliter Interval 0.0 to 1500.0	804.0 Nanograms per milliliter Interval 103.0 to 2610.0
Plasma Concentration of GSK3640254-Part 1 3 hours	—	563.5 Nanograms per milliliter Interval 16.7 to 1780.0	965.0 Nanograms per milliliter Interval 321.0 to 2210.0
Plasma Concentration of GSK3640254-Part 1 3.5 hours	—	724.0 Nanograms per milliliter Interval 44.3 to 1560.0	1105 Nanograms per milliliter Interval 482.0 to 2190.0
Plasma Concentration of GSK3640254-Part 1 4 hours	—	798.5 Nanograms per milliliter Interval 80.1 to 1660.0	1190 Nanograms per milliliter Interval 569.0 to 1940.0
Plasma Concentration of GSK3640254-Part 1 4.5 hours	—	964.5 Nanograms per milliliter Interval 135.0 to 1900.0	1270 Nanograms per milliliter Interval 567.0 to 1890.0
Plasma Concentration of GSK3640254-Part 1 5 hours	—	1047 Nanograms per milliliter Interval 170.0 to 1840.0	1195 Nanograms per milliliter Interval 479.0 to 1810.0
Plasma Concentration of GSK3640254-Part 1 6 hours	—	1013 Nanograms per milliliter Interval 385.0 to 1750.0	992.0 Nanograms per milliliter Interval 437.0 to 1710.0
Plasma Concentration of GSK3640254-Part 1 8 hours	—	981.0 Nanograms per milliliter Interval 298.0 to 1610.0	895.0 Nanograms per milliliter Interval 385.0 to 1500.0
Plasma Concentration of GSK3640254-Part 1 12 hours	—	817.0 Nanograms per milliliter Interval 253.0 to 1470.0	787.0 Nanograms per milliliter Interval 290.0 to 1210.0
Plasma Concentration of GSK3640254-Part 1 24 hours	—	565.5 Nanograms per milliliter Interval 162.0 to 889.0	582.0 Nanograms per milliliter Interval 202.0 to 887.0
Plasma Concentration of GSK3640254-Part 1 48 hours	—	286.0 Nanograms per milliliter Interval 81.9 to 483.0	286.0 Nanograms per milliliter Interval 121.0 to 509.0
Plasma Concentration of GSK3640254-Part 1 72 hours	—	159.0 Nanograms per milliliter Interval 47.3 to 284.0	150.0 Nanograms per milliliter Interval 75.1 to 271.0
Plasma Concentration of GSK3640254-Part 1 96 hours	—	78.10 Nanograms per milliliter Interval 26.0 to 197.0	72.80 Nanograms per milliliter Interval 34.0 to 172.0

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Tlag for GSK3640254-Part 2	0.048 Hours Standard Deviation 0.2182	0.050 Hours Standard Deviation 0.2236	0.000 Hours Standard Deviation 0.0000

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=10 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
T1/2 for GSK3640254-Part 2	24.833 Hours Geometric Coefficient of Variation 15.7	24.921 Hours Geometric Coefficient of Variation 18.0	25.669 Hours Geometric Coefficient of Variation 12.7

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=10 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
CL/F for GSK3640254-Part 2	5.417 Liter per hour Geometric Coefficient of Variation 35.9	4.878 Liter per hour Geometric Coefficient of Variation 42.2	14.85 Liter per hour Geometric Coefficient of Variation 58.2

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=10 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Vz/F for GSK3640254-Part 2	194.1 Liters Geometric Coefficient of Variation 35.9	175.4 Liters Geometric Coefficient of Variation 43.4	550.1 Liters Geometric Coefficient of Variation 66.3

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Concentration Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis.

Outcome measures

Outcome measures
Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Plasma Concentration of GSK3640254-Part 2 24 hours	580.0 Nanograms per milliliter Interval 276.0 to 1070.0	627.5 Nanograms per milliliter Interval 256.0 to 1150.0	177.0 Nanograms per milliliter Interval 49.9 to 722.0
Plasma Concentration of GSK3640254-Part 2 pre-dose	NA Nanograms per milliliter Interval to 14.7 Median and lower limit could not be calculated as the values were below the lower limit of quantification.	6.370 Nanograms per milliliter Interval 0.0 to 31.6	0 Nanograms per milliliter Interval 0.0 to 12.8
Plasma Concentration of GSK3640254-Part 2 1 hour	92.30 Nanograms per milliliter Interval 0.0 to 1960.0	39.25 Nanograms per milliliter Interval 0.0 to 504.0	38.70 Nanograms per milliliter Interval 7.27 to 268.0
Plasma Concentration of GSK3640254-Part 2 1.5 hours	239.0 Nanograms per milliliter Interval 9.88 to 2000.0	306.0 Nanograms per milliliter Interval 9.18 to 1360.0	84.10 Nanograms per milliliter Interval 18.3 to 496.0
Plasma Concentration of GSK3640254-Part 2 2 hours	574.0 Nanograms per milliliter Interval 27.0 to 1790.0	733.0 Nanograms per milliliter Interval 37.7 to 1920.0	121.0 Nanograms per milliliter Interval 23.9 to 648.0
Plasma Concentration of GSK3640254-Part 2 2.5 hours	684.0 Nanograms per milliliter Interval 65.0 to 1770.0	1075 Nanograms per milliliter Interval 193.0 to 2320.0	194.0 Nanograms per milliliter Interval 31.0 to 831.0
Plasma Concentration of GSK3640254-Part 2 3 hours	724.0 Nanograms per milliliter Interval 125.0 to 2040.0	1195 Nanograms per milliliter Interval 434.0 to 2320.0	270.0 Nanograms per milliliter Interval 34.1 to 1050.0
Plasma Concentration of GSK3640254-Part 2 3.5 hours	785.0 Nanograms per milliliter Interval 212.0 to 2070.0	1250 Nanograms per milliliter Interval 525.0 to 2310.0	326.0 Nanograms per milliliter Interval 40.0 to 1260.0
Plasma Concentration of GSK3640254-Part 2 4 hours	833.0 Nanograms per milliliter Interval 230.0 to 1910.0	1305 Nanograms per milliliter Interval 607.0 to 2590.0	358.0 Nanograms per milliliter Interval 58.9 to 1270.0
Plasma Concentration of GSK3640254-Part 2 4.5 hours	866.0 Nanograms per milliliter Interval 272.0 to 1630.0	1245 Nanograms per milliliter Interval 636.0 to 2330.0	324.0 Nanograms per milliliter Interval 77.4 to 1480.0
Plasma Concentration of GSK3640254-Part 2 5 hours	845.0 Nanograms per milliliter Interval 355.0 to 1620.0	1275 Nanograms per milliliter Interval 590.0 to 2470.0	322.0 Nanograms per milliliter Interval 71.7 to 1420.0
Plasma Concentration of GSK3640254-Part 2 6 hours	968.0 Nanograms per milliliter Interval 562.0 to 1440.0	1195 Nanograms per milliliter Interval 528.0 to 2450.0	290.0 Nanograms per milliliter Interval 75.8 to 1350.0
Plasma Concentration of GSK3640254-Part 2 8 hours	845.0 Nanograms per milliliter Interval 427.0 to 1370.0	950.5 Nanograms per milliliter Interval 457.0 to 2110.0	255.0 Nanograms per milliliter Interval 57.9 to 1160.0
Plasma Concentration of GSK3640254-Part 2 12 hours	734.0 Nanograms per milliliter Interval 376.0 to 1420.0	773.0 Nanograms per milliliter Interval 363.0 to 1730.0	217.0 Nanograms per milliliter Interval 50.6 to 903.0
Plasma Concentration of GSK3640254-Part 2 48 hours	287.0 Nanograms per milliliter Interval 149.0 to 683.0	335.5 Nanograms per milliliter Interval 123.0 to 533.0	98.60 Nanograms per milliliter Interval 35.4 to 327.0
Plasma Concentration of GSK3640254-Part 2 72 hours	145.0 Nanograms per milliliter Interval 68.0 to 375.0	171.5 Nanograms per milliliter Interval 57.7 to 292.0	52.50 Nanograms per milliliter Interval 28.3 to 153.0
Plasma Concentration of GSK3640254-Part 2 96 hours	62.20 Nanograms per milliliter Interval 35.9 to 224.0	79.75 Nanograms per milliliter Interval 26.4 to 203.0	31.30 Nanograms per milliliter Interval 14.8 to 80.7

Adverse Events

Part 1: GSK3640254 200 mg Capsules

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 1: GSK3640254 200 mg Tablets

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part 2: GSK3640254 200 mg Tablet (Moderate Fat)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 2: GSK3640254 200 mg Tablet (Fasted)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 2: GSK3640254 200 mg Tablet (High Fat)

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Part 1: GSK3640254 200 mg Capsules n=18 participants at risk Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 participants at risk Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (Moderate Fat) n=20 participants at risk Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1, 2 or 3.	Part 2: GSK3640254 200 mg Tablet (Fasted) n=19 participants at risk Participants were administered a single dose of GSK3640254 200 mg tablets, orally under fasted conditions on Day 1 in Period 1, 2 or 3.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 participants at risk Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Eye disorders Eye irritation	0.00% 0/18 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	5.6% 1/18 • Number of events 1 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/20 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/19 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/21 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.
Gastrointestinal disorders Diarrhoea	0.00% 0/18 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/18 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/20 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/19 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	9.5% 2/21 • Number of events 2 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.

Additional Information

GSK Response Center

ViiV Healthcare

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Baseline; n=18, 18	—	232.5 10^9 cells per liter Standard Deviation 43.58	232.5 10^9 cells per liter Standard Deviation 43.58
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Day 2; n=18, 18	—	238.2 10^9 cells per liter Standard Deviation 49.37	241.5 10^9 cells per liter Standard Deviation 48.56
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Baseline; n=18, 18	—	0.032 10^9 cells per liter Standard Deviation 0.0134	0.032 10^9 cells per liter Standard Deviation 0.0134
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Day 2; n=18, 18	—	0.030 10^9 cells per liter Standard Deviation 0.0137	0.030 10^9 cells per liter Standard Deviation 0.077
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Day 5; n=9, 9	—	0.027 10^9 cells per liter Standard Deviation 0.0071	0.030 10^9 cells per liter Standard Deviation 0.0166
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Baseline; n=18, 18	—	0.100 10^9 cells per liter Standard Deviation 0.0832	0.100 10^9 cells per liter Standard Deviation 0.0832
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Day 2; n=18, 18	—	0.116 10^9 cells per liter Standard Deviation 0.0911	0.122 10^9 cells per liter Standard Deviation 0.1101
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Day 5; n=9, 9	—	0.133 10^9 cells per liter Standard Deviation 0.1227	0.118 10^9 cells per liter Standard Deviation 0.0769
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Baseline; n=18, 18	—	1.617 10^9 cells per liter Standard Deviation 0.3975	1.617 10^9 cells per liter Standard Deviation 0.3975
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Day 2; n=18, 18	—	1.726 10^9 cells per liter Standard Deviation 0.3852	1.744 10^9 cells per liter Standard Deviation 0.4791
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Day 5; n=9, 9	—	1.639 10^9 cells per liter Standard Deviation 0.3536	2.074 10^9 cells per liter Standard Deviation 0.6328
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Baseline; n=18, 18	—	0.403 10^9 cells per liter Standard Deviation 0.0859	0.403 10^9 cells per liter Standard Deviation 0.0859
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Day 2; n=18, 18	—	0.409 10^9 cells per liter Standard Deviation 0.0955	0.412 10^9 cells per liter Standard Deviation 0.1379
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Day 5; n=9, 9	—	0.386 10^9 cells per liter Standard Deviation 0.1100	0.411 10^9 cells per liter Standard Deviation 0.1071
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Baseline; n=18, 18	—	3.406 10^9 cells per liter Standard Deviation 1.0436	3.406 10^9 cells per liter Standard Deviation 1.0436
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Day 2; n=18, 18	—	2.925 10^9 cells per liter Standard Deviation 0.6617	2.723 10^9 cells per liter Standard Deviation 0.9257
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Day 5; n=9, 9	—	2.864 10^9 cells per liter Standard Deviation 0.7372	3.108 10^9 cells per liter Standard Deviation 0.5724
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Day 5; n=9, 9	—	267.1 10^9 cells per liter Standard Deviation 52.86	231.4 10^9 cells per liter Standard Deviation 38.51

Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Day 5; n=7, 5, 7	0.049 10^9 cells per liter Standard Deviation 0.0219	0.047 10^9 cells per liter Standard Deviation 0.0287	0.036 10^9 cells per liter Standard Deviation 0.0167
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Baseline; n=20, 19, 21	0.141 10^9 cells per liter Standard Deviation 0.0879	0.141 10^9 cells per liter Standard Deviation 0.0879	0.141 10^9 cells per liter Standard Deviation 0.0879
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Day 2; n=20, 19, 21	0.150 10^9 cells per liter Standard Deviation 0.1109	0.136 10^9 cells per liter Standard Deviation 0.0922	0.135 10^9 cells per liter Standard Deviation 0.0837
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Baseline; n=20, 19, 21	0.042 10^9 cells per liter Standard Deviation 0.0260	0.042 10^9 cells per liter Standard Deviation 0.0260	0.042 10^9 cells per liter Standard Deviation 0.0260
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Day 2; n=20, 19, 21	0.043 10^9 cells per liter Standard Deviation 0.0215	0.041 10^9 cells per liter Standard Deviation 0.0276	0.040 10^9 cells per liter Standard Deviation 0.0200
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Day 5; n=7, 5, 7	0.151 10^9 cells per liter Standard Deviation 0.0915	0.146 10^9 cells per liter Standard Deviation 0.1050	0.090 10^9 cells per liter Standard Deviation 0.0374
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Baseline; n=20, 19, 21	1.650 10^9 cells per liter Standard Deviation 0.4926	1.650 10^9 cells per liter Standard Deviation 0.4926	1.650 10^9 cells per liter Standard Deviation 0.4926
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Day 2; n=20, 19, 21	1.583 10^9 cells per liter Standard Deviation 0.3748	1.576 10^9 cells per liter Standard Deviation 0.3410	1.684 10^9 cells per liter Standard Deviation 0.4939
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Day 5; n=7, 5, 7	1.923 10^9 cells per liter Standard Deviation 0.4442	1.806 10^9 cells per liter Standard Deviation 0.3577	1.472 10^9 cells per liter Standard Deviation 0.2765
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Baseline; n=20, 19, 21	0.469 10^9 cells per liter Standard Deviation 0.1445	0.469 10^9 cells per liter Standard Deviation 0.1445	0.469 10^9 cells per liter Standard Deviation 0.1445
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Day 2; n=20, 19, 21	0.446 10^9 cells per liter Standard Deviation 0.1553	0.446 10^9 cells per liter Standard Deviation 0.1589	0.449 10^9 cells per liter Standard Deviation 0.1171
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Day 5; n=7, 5, 7	0.504 10^9 cells per liter Standard Deviation 0.1130	0.530 10^9 cells per liter Standard Deviation 0.1788	0.422 10^9 cells per liter Standard Deviation 0.0669
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Baseline; n=20, 19, 21	3.246 10^9 cells per liter Standard Deviation 1.0719	3.246 10^9 cells per liter Standard Deviation 1.0719	3.246 10^9 cells per liter Standard Deviation 1.0719
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Day 2; n=20, 19, 21	2.947 10^9 cells per liter Standard Deviation 1.0824	2.908 10^9 cells per liter Standard Deviation 1.1660	2.904 10^9 cells per liter Standard Deviation 0.8595
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Day 5; n=7, 5, 7	3.877 10^9 cells per liter Standard Deviation 1.4452	2.464 10^9 cells per liter Standard Deviation 0.9204	3.472 10^9 cells per liter Standard Deviation 0.8987
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Baseline; n=20, 19, 21	259.9 10^9 cells per liter Standard Deviation 63.91	259.9 10^9 cells per liter Standard Deviation 63.91	259.9 10^9 cells per liter Standard Deviation 63.91
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Day 2; n=20, 19, 21	281.3 10^9 cells per liter Standard Deviation 59.88	284.2 10^9 cells per liter Standard Deviation 55.70	270.6 10^9 cells per liter Standard Deviation 60.80
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Day 5; n=7, 5, 7	291.3 10^9 cells per liter Standard Deviation 48.52	255.9 10^9 cells per liter Standard Deviation 47.27	272.4 10^9 cells per liter Standard Deviation 77.61

Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Baseline; n=18, 18	—	9.5 Millimoles per liter Standard Deviation 1.76	9.5 Millimoles per liter Standard Deviation 1.76
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Baseline; n=18, 18	—	4.00 Millimoles per liter Standard Deviation 0.230	4.00 Millimoles per liter Standard Deviation 0.230
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Baseline; n=18, 18	—	2.327 Millimoles per liter Standard Deviation 0.0451	2.327 Millimoles per liter Standard Deviation 0.0451
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Day 2; n=18, 18	—	2.352 Millimoles per liter Standard Deviation 0.0536	2.378 Millimoles per liter Standard Deviation 0.0830
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Day 5; n=9, 9	—	2.343 Millimoles per liter Standard Deviation 0.0705	2.313 Millimoles per liter Standard Deviation 0.0559
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Baseline; n=18, 18	—	4.987 Millimoles per liter Standard Deviation 0.3833	4.987 Millimoles per liter Standard Deviation 0.3833
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Day 2; n=18, 18	—	4.842 Millimoles per liter Standard Deviation 0.3451	4.706 Millimoles per liter Standard Deviation 0.2996
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Day 5; n=9, 9	—	4.607 Millimoles per liter Standard Deviation 0.2889	4.600 Millimoles per liter Standard Deviation 0.2182
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Day 2; n=18, 18	—	4.27 Millimoles per liter Standard Deviation 0.256	4.33 Millimoles per liter Standard Deviation 0.379
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Day 5; n=9, 9	—	4.18 Millimoles per liter Standard Deviation 0.228	4.13 Millimoles per liter Standard Deviation 0.320
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Baseline; n=18, 18	—	136.9 Millimoles per liter Standard Deviation 2.19	136.9 Millimoles per liter Standard Deviation 2.19
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Day 2; n=18, 18	—	138.5 Millimoles per liter Standard Deviation 1.54	138.9 Millimoles per liter Standard Deviation 1.75
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Day 5; n=9, 9	—	138.2 Millimoles per liter Standard Deviation 1.48	138.8 Millimoles per liter Standard Deviation 1.48
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Baseline; n=18, 18	—	102.3 Millimoles per liter Standard Deviation 1.64	102.3 Millimoles per liter Standard Deviation 1.64
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Day 2; n=18, 18	—	102.5 Millimoles per liter Standard Deviation 1.69	102.9 Millimoles per liter Standard Deviation 1.66
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Day 5; n=9, 9	—	101.9 Millimoles per liter Standard Deviation 1.76	101.8 Millimoles per liter Standard Deviation 1.56
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Baseline; n=18, 18	—	1.121 Millimoles per liter Standard Deviation 0.1289	1.121 Millimoles per liter Standard Deviation 0.1289
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Day 2; n=18, 18	—	1.197 Millimoles per liter Standard Deviation 0.1058	1.197 Millimoles per liter Standard Deviation 0.1365
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Day 5; n=9, 9	—	1.173 Millimoles per liter Standard Deviation 0.1413	1.234 Millimoles per liter Standard Deviation 0.0963
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Baseline; n=18, 18	—	3.728 Millimoles per liter Standard Deviation 1.0672	3.728 Millimoles per liter Standard Deviation 1.0672
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Day 2; n=18, 18	—	4.747 Millimoles per liter Standard Deviation 0.8949	4.654 Millimoles per liter Standard Deviation 0.8997
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Day 5; n=9, 9	—	5.053 Millimoles per liter Standard Deviation 0.9143	4.729 Millimoles per liter Standard Deviation 0.7928
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Baseline; n=18, 18	—	1.026 Millimoles per liter Standard Deviation 0.6064	1.026 Millimoles per liter Standard Deviation 0.6064
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Day 2; n=18, 18	—	1.127 Millimoles per liter Standard Deviation 0.3973	1.036 Millimoles per liter Standard Deviation 0.3982
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Day 5; n=9, 9	—	1.029 Millimoles per liter Standard Deviation 0.3389	0.904 Millimoles per liter Standard Deviation 0.2605
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Baseline; n=18, 18	—	4.549 Millimoles per liter Standard Deviation 0.9656	4.549 Millimoles per liter Standard Deviation 0.9656
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Day 2; n=18, 18	—	4.544 Millimoles per liter Standard Deviation 0.8853	4.632 Millimoles per liter Standard Deviation 0.9164
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Day 5; n=9, 9	—	4.519 Millimoles per liter Standard Deviation 0.6212	4.330 Millimoles per liter Standard Deviation 1.1611
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Day 2; n=18, 18	—	10.1 Millimoles per liter Standard Deviation 1.28	10.0 Millimoles per liter Standard Deviation 1.08
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Day 5; n=9, 9	—	10.7 Millimoles per liter Standard Deviation 0.87	10.1 Millimoles per liter Standard Deviation 0.93
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Baseline; n=18, 18	—	29.1 Millimoles per liter Standard Deviation 2.00	29.1 Millimoles per liter Standard Deviation 2.00
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Day 2; n=18, 18	—	30.1 Millimoles per liter Standard Deviation 1.86	30.2 Millimoles per liter Standard Deviation 1.58
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Day 5; n=9, 9	—	29.9 Millimoles per liter Standard Deviation 1.36	31.0 Millimoles per liter Standard Deviation 1.87

Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALT; Baseline; n=18, 18	—	22.1 International units per liter Standard Deviation 12.44	22.1 International units per liter Standard Deviation 12.44
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALT; Day 2; n=18, 18	—	21.8 International units per liter Standard Deviation 13.38	18.4 International units per liter Standard Deviation 9.28
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALT; Day 5; n=9, 9	—	20.6 International units per liter Standard Deviation 14.51	19.6 International units per liter Standard Deviation 7.07
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALP; Baseline; n=18, 18	—	54.6 International units per liter Standard Deviation 11.32	54.6 International units per liter Standard Deviation 11.32
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALP; Day 2; n=18, 18	—	52.1 International units per liter Standard Deviation 11.59	52.1 International units per liter Standard Deviation 10.96
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALP; Day 5; n=9, 9	—	55.2 International units per liter Standard Deviation 12.34	50.3 International units per liter Standard Deviation 5.87
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 AST; Baseline; n=18, 18	—	21.7 International units per liter Standard Deviation 8.39	21.7 International units per liter Standard Deviation 8.39
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 AST; Day 2; n=18, 18	—	19.1 International units per liter Standard Deviation 6.65	17.6 International units per liter Standard Deviation 4.94
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 AST; Day 5; n=9, 9	—	19.0 International units per liter Standard Deviation 4.30	17.0 International units per liter Standard Deviation 3.71
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 GGT; Baseline; n=18, 18	—	19.3 International units per liter Standard Deviation 11.26	19.3 International units per liter Standard Deviation 11.26
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 GGT; Day 2; n=18, 18	—	18.1 International units per liter Standard Deviation 11.18	18.9 International units per liter Standard Deviation 11.60
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 GGT; Day 5; n=9, 9	—	19.2 International units per liter Standard Deviation 13.07	15.8 International units per liter Standard Deviation 6.85
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 CK; Baseline; n=18, 18	—	126.9 International units per liter Standard Deviation 62.61	126.9 International units per liter Standard Deviation 62.61
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 CK; Day 2; n=18, 18	—	87.4 International units per liter Standard Deviation 40.30	92.2 International units per liter Standard Deviation 44.64
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 CK; Day 5; n=9, 9	—	86.0 International units per liter Standard Deviation 35.27	98.3 International units per liter Standard Deviation 50.21
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 LDH; Baseline; n=18, 18	—	136.4 International units per liter Standard Deviation 20.82	136.4 International units per liter Standard Deviation 20.82
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 LDH; Day 2; n=18, 18	—	117.7 International units per liter Standard Deviation 21.06	120.4 International units per liter Standard Deviation 21.17
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 LDH; Day 5; n=9, 9	—	122.0 International units per liter Standard Deviation 20.91	123.6 International units per liter Standard Deviation 18.53

Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Baseline; n=20, 19, 21	2.312 Millimoles per liter Standard Deviation 0.0973	2.312 Millimoles per liter Standard Deviation 0.0973	2.312 Millimoles per liter Standard Deviation 0.0973
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Day 2; n=20, 19, 21	2.390 Millimoles per liter Standard Deviation 0.0695	2.408 Millimoles per liter Standard Deviation 0.0670	2.369 Millimoles per liter Standard Deviation 0.0671
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Day 5; n=7, 5, 7	2.367 Millimoles per liter Standard Deviation 0.0640	2.446 Millimoles per liter Standard Deviation 0.0500	2.324 Millimoles per liter Standard Deviation 0.0439
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Baseline; n=20, 19, 21	4.745 Millimoles per liter Standard Deviation 0.3160	4.745 Millimoles per liter Standard Deviation 0.3160	4.745 Millimoles per liter Standard Deviation 0.3160
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Day 2; n=20, 19, 21	4.775 Millimoles per liter Standard Deviation 0.2039	4.716 Millimoles per liter Standard Deviation 0.2093	4.861 Millimoles per liter Standard Deviation 0.2250
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Day 5; n=7, 5, 7	4.926 Millimoles per liter Standard Deviation 0.2224	4.574 Millimoles per liter Standard Deviation 0.3675	4.608 Millimoles per liter Standard Deviation 0.3518
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Baseline; n=20, 19, 21	4.16 Millimoles per liter Standard Deviation 0.225	4.16 Millimoles per liter Standard Deviation 0.225	4.16 Millimoles per liter Standard Deviation 0.225
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Day 2; n=20, 19, 21	4.14 Millimoles per liter Standard Deviation 0.240	4.26 Millimoles per liter Standard Deviation 0.244	4.17 Millimoles per liter Standard Deviation 0.281
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Day 5; n=7, 5, 7	4.17 Millimoles per liter Standard Deviation 0.236	3.84 Millimoles per liter Standard Deviation 0.251	3.94 Millimoles per liter Standard Deviation 0.230
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Baseline; n=20, 19, 21	138.4 Millimoles per liter Standard Deviation 1.56	138.4 Millimoles per liter Standard Deviation 1.56	138.4 Millimoles per liter Standard Deviation 1.56
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Day 2; n=20, 19, 21	137.4 Millimoles per liter Standard Deviation 1.24	137.9 Millimoles per liter Standard Deviation 2.00	137.9 Millimoles per liter Standard Deviation 2.58
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Day 5; n=7, 5, 7	136.3 Millimoles per liter Standard Deviation 1.89	137.3 Millimoles per liter Standard Deviation 1.11	136.2 Millimoles per liter Standard Deviation 2.59
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Baseline; n=20, 19, 21	102.4 Millimoles per liter Standard Deviation 1.72	102.4 Millimoles per liter Standard Deviation 1.72	102.4 Millimoles per liter Standard Deviation 1.72
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Day 2; n=20, 19, 21	102.0 Millimoles per liter Standard Deviation 2.09	102.0 Millimoles per liter Standard Deviation 1.81	102.2 Millimoles per liter Standard Deviation 2.06
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Day 5; n=7, 5, 7	100.4 Millimoles per liter Standard Deviation 2.37	100.3 Millimoles per liter Standard Deviation 1.38	101.8 Millimoles per liter Standard Deviation 2.28
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Baseline; n=20, 19, 21	1.100 Millimoles per liter Standard Deviation 0.1813	1.100 Millimoles per liter Standard Deviation 0.1813	1.100 Millimoles per liter Standard Deviation 0.1813
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Day 2; n=20, 19, 21	1.176 Millimoles per liter Standard Deviation 0.1730	1.191 Millimoles per liter Standard Deviation 0.1827	1.177 Millimoles per liter Standard Deviation 0.1535
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Day 5; n=7, 5, 7	1.117 Millimoles per liter Standard Deviation 0.1612	1.297 Millimoles per liter Standard Deviation 0.1577	1.158 Millimoles per liter Standard Deviation 0.2958
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Baseline; n=20, 19, 21	4.190 Millimoles per liter Standard Deviation 0.9187	4.190 Millimoles per liter Standard Deviation 0.9187	4.190 Millimoles per liter Standard Deviation 0.9187
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Day 2; n=20, 19, 21	4.403 Millimoles per liter Standard Deviation 0.8736	4.526 Millimoles per liter Standard Deviation 0.7144	4.531 Millimoles per liter Standard Deviation 0.8261
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Day 5; n=7, 5, 7	5.050 Millimoles per liter Standard Deviation 1.2701	4.921 Millimoles per liter Standard Deviation 0.9744	4.768 Millimoles per liter Standard Deviation 0.4098
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Baseline; n=20, 19, 21	0.828 Millimoles per liter Standard Deviation 0.3752	0.828 Millimoles per liter Standard Deviation 0.3752	0.828 Millimoles per liter Standard Deviation 0.3752
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Day 2; n=20, 19, 21	0.890 Millimoles per liter Standard Deviation 0.4024	0.957 Millimoles per liter Standard Deviation 0.3872	0.994 Millimoles per liter Standard Deviation 0.3875
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Day 5; n=7, 5, 7	1.363 Millimoles per liter Standard Deviation 0.6417	0.894 Millimoles per liter Standard Deviation 0.3072	0.774 Millimoles per liter Standard Deviation 0.2790
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Baseline; n=20, 19, 21	4.533 Millimoles per liter Standard Deviation 0.8776	4.533 Millimoles per liter Standard Deviation 0.8776	4.533 Millimoles per liter Standard Deviation 0.8776
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Day 2; n=20, 19, 21	4.610 Millimoles per liter Standard Deviation 0.8031	4.652 Millimoles per liter Standard Deviation 0.7742	4.639 Millimoles per liter Standard Deviation 0.9975
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Day 5; n=7, 5, 7	4.454 Millimoles per liter Standard Deviation 0.8948	4.520 Millimoles per liter Standard Deviation 0.5269	3.962 Millimoles per liter Standard Deviation 0.8236
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Baseline; n=20, 19, 21	11.3 Millimoles per liter Standard Deviation 1.53	11.3 Millimoles per liter Standard Deviation 1.53	11.3 Millimoles per liter Standard Deviation 1.53
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Day 2; n=20, 19, 21	10.8 Millimoles per liter Standard Deviation 1.54	10.6 Millimoles per liter Standard Deviation 1.15	10.4 Millimoles per liter Standard Deviation 1.17
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Day 5; n=7, 5, 7	11.9 Millimoles per liter Standard Deviation 1.68	11.7 Millimoles per liter Standard Deviation 2.43	10.8 Millimoles per liter Standard Deviation 0.84
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Baseline; n=20, 19, 21	28.7 Millimoles per liter Standard Deviation 2.00	28.7 Millimoles per liter Standard Deviation 2.00	28.7 Millimoles per liter Standard Deviation 2.00
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Day 2; n=20, 19, 21	28.6 Millimoles per liter Standard Deviation 2.20	29.6 Millimoles per liter Standard Deviation 1.67	29.5 Millimoles per liter Standard Deviation 1.78
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Day 5; n=7, 5, 7	28.1 Millimoles per liter Standard Deviation 1.57	29.3 Millimoles per liter Standard Deviation 1.50	27.6 Millimoles per liter Standard Deviation 2.19

Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Day 5; n=7, 5, 7	145.4 International units per liter Standard Deviation 170.90	135.7 International units per liter Standard Deviation 108.77	136.4 International units per liter Standard Deviation 109.71
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Baseline; n=20, 19, 21	19.0 International units per liter Standard Deviation 11.01	19.0 International units per liter Standard Deviation 11.01	19.0 International units per liter Standard Deviation 11.01
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Day 2; n=20, 19, 21	16.8 International units per liter Standard Deviation 9.20	14.4 International units per liter Standard Deviation 6.06	17.3 International units per liter Standard Deviation 9.49
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Day 5; n=7, 5, 7	22.7 International units per liter Standard Deviation 14.36	16.7 International units per liter Standard Deviation 8.04	11.0 International units per liter Standard Deviation 2.74
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Baseline; n=20, 19, 21	50.4 International units per liter Standard Deviation 16.47	50.4 International units per liter Standard Deviation 16.47	50.4 International units per liter Standard Deviation 16.47
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Day 2; n=20, 19, 21	56.7 International units per liter Standard Deviation 18.33	56.5 International units per liter Standard Deviation 17.52	57.4 International units per liter Standard Deviation 17.03
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Day 5; n=7, 5, 7	55.0 International units per liter Standard Deviation 13.69	49.6 International units per liter Standard Deviation 22.40	56.4 International units per liter Standard Deviation 9.58
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Baseline; n=20, 19, 21	18.0 International units per liter Standard Deviation 6.01	18.0 International units per liter Standard Deviation 6.01	18.0 International units per liter Standard Deviation 6.01
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Day 2; n=20, 19, 21	16.0 International units per liter Standard Deviation 4.11	14.9 International units per liter Standard Deviation 3.01	15.8 International units per liter Standard Deviation 4.29
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Day 5; n=7, 5, 7	16.6 International units per liter Standard Deviation 3.78	16.7 International units per liter Standard Deviation 4.42	14.0 International units per liter Standard Deviation 2.12
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Baseline; n=20, 19, 21	17.1 International units per liter Standard Deviation 5.80	17.1 International units per liter Standard Deviation 5.80	17.1 International units per liter Standard Deviation 5.80
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Day 2; n=20, 19, 21	17.3 International units per liter Standard Deviation 7.67	16.5 International units per liter Standard Deviation 5.56	17.4 International units per liter Standard Deviation 6.15
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Day 5; n=7, 5, 7	21.6 International units per liter Standard Deviation 13.31	14.9 International units per liter Standard Deviation 3.72	14.8 International units per liter Standard Deviation 0.45
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Baseline; n=20, 19, 21	118.8 International units per liter Standard Deviation 79.80	118.8 International units per liter Standard Deviation 79.80	118.8 International units per liter Standard Deviation 79.80
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Day 2; n=20, 19, 21	106.2 International units per liter Standard Deviation 81.94	106.2 International units per liter Standard Deviation 80.82	114.9 International units per liter Standard Deviation 101.61
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Baseline; n=20, 19, 21	133.6 International units per liter Standard Deviation 19.21	133.6 International units per liter Standard Deviation 19.21	133.6 International units per liter Standard Deviation 19.21
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Day 2; n=20, 19, 21	122.1 International units per liter Standard Deviation 18.56	121.1 International units per liter Standard Deviation 17.48	121.5 International units per liter Standard Deviation 21.60
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Day 5; n=7, 5, 7	126.0 International units per liter Standard Deviation 22.84	118.4 International units per liter Standard Deviation 16.63	110.0 International units per liter Standard Deviation 12.29

Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Day 2; n=18, 18	—	0.025 Millimoles per liter Standard Deviation 0.0534	0.051 Millimoles per liter Standard Deviation 0.0828
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Day 5; n=9, 9	—	0.019 Millimoles per liter Standard Deviation 0.0762	-0.016 Millimoles per liter Standard Deviation 0.0548
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Day 2; n=18, 18	—	-0.145 Millimoles per liter Standard Deviation 0.3134	-0.281 Millimoles per liter Standard Deviation 0.4796
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Day 5; n=9, 9	—	-0.252 Millimoles per liter Standard Deviation 0.4474	-0.514 Millimoles per liter Standard Deviation 0.3475
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Day 2; n=18, 18	—	0.27 Millimoles per liter Standard Deviation 0.278	0.33 Millimoles per liter Standard Deviation 0.331
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Day 5; n=9, 9	—	0.30 Millimoles per liter Standard Deviation 0.296	0.01 Millimoles per liter Standard Deviation 0.247
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Day 2; n=18, 18	—	1.6 Millimoles per liter Standard Deviation 2.30	2.0 Millimoles per liter Standard Deviation 2.28
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Day 5; n=9, 9	—	1.8 Millimoles per liter Standard Deviation 2.77	1.4 Millimoles per liter Standard Deviation 1.33
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Day 2; n=18, 18	—	0.2 Millimoles per liter Standard Deviation 2.05	0.7 Millimoles per liter Standard Deviation 2.22
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Day 5; n=9, 9	—	-0.2 Millimoles per liter Standard Deviation 2.33	-0.7 Millimoles per liter Standard Deviation 1.73
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Day 2; n=18, 18	—	0.077 Millimoles per liter Standard Deviation 0.1177	0.077 Millimoles per liter Standard Deviation 0.1223
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Day 5; n=9, 9	—	0.077 Millimoles per liter Standard Deviation 0.1331	0.090 Millimoles per liter Standard Deviation 0.1282
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Day 2; n=18, 18	—	1.019 Millimoles per liter Standard Deviation 0.9553	0.926 Millimoles per liter Standard Deviation 1.0408
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Day 5; n=9, 9	—	1.178 Millimoles per liter Standard Deviation 1.0554	1.148 Millimoles per liter Standard Deviation 0.6297
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Day 2; n=18, 18	—	0.101 Millimoles per liter Standard Deviation 0.4182	0.010 Millimoles per liter Standard Deviation 0.4769
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Day 5; n=9, 9	—	0.102 Millimoles per liter Standard Deviation 0.2870	-0.221 Millimoles per liter Standard Deviation 0.5382
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Day 2; n=18, 18	—	-0.005 Millimoles per liter Standard Deviation 0.3983	0.082 Millimoles per liter Standard Deviation 0.4981
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Day 5; n=9, 9	—	-0.148 Millimoles per liter Standard Deviation 0.4463	-0.102 Millimoles per liter Standard Deviation 0.6612
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Day 2; n=18, 18	—	0.6 Millimoles per liter Standard Deviation 2.03	0.5 Millimoles per liter Standard Deviation 1.95
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Day 5; n=9, 9	—	0.8 Millimoles per liter Standard Deviation 2.64	1.0 Millimoles per liter Standard Deviation 1.22
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Day 2; n=18, 18	—	0.9 Millimoles per liter Standard Deviation 2.60	1.1 Millimoles per liter Standard Deviation 2.10
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Day 5; n=9, 9	—	1.4 Millimoles per liter Standard Deviation 2.60	1.2 Millimoles per liter Standard Deviation 1.56

Measure	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Day 5; n=7, 5, 7	-1.4 Millimoles per liter Standard Deviation 3.10	-1.9 Millimoles per liter Standard Deviation 0.69	-2.0 Millimoles per liter Standard Deviation 1.41
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Day 2; n=20, 19, 21	-0.3 Millimoles per liter Standard Deviation 2.29	-0.5 Millimoles per liter Standard Deviation 1.67	-0.2 Millimoles per liter Standard Deviation 1.78
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Day 5; n=7, 5, 7	-1.0 Millimoles per liter Standard Deviation 2.89	-1.9 Millimoles per liter Standard Deviation 0.90	-2.2 Millimoles per liter Standard Deviation 1.10
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Day 2; n=20, 19, 21	0.076 Millimoles per liter Standard Deviation 0.0815	0.087 Millimoles per liter Standard Deviation 0.0836	0.065 Millimoles per liter Standard Deviation 0.0973
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Day 5; n=7, 5, 7	0.074 Millimoles per liter Standard Deviation 0.0820	0.060 Millimoles per liter Standard Deviation 0.0856	0.124 Millimoles per liter Standard Deviation 0.0953
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Day 2; n=20, 19, 21	0.213 Millimoles per liter Standard Deviation 0.9258	0.307 Millimoles per liter Standard Deviation 0.8732	0.257 Millimoles per liter Standard Deviation 0.9884
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Day 5; n=7, 5, 7	0.506 Millimoles per liter Standard Deviation 0.9007	0.783 Millimoles per liter Standard Deviation 1.1942	0.684 Millimoles per liter Standard Deviation 0.7695
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Day 2; n=20, 19, 21	0.062 Millimoles per liter Standard Deviation 0.2884	0.115 Millimoles per liter Standard Deviation 0.2130	0.127 Millimoles per liter Standard Deviation 0.2750
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Day 5; n=7, 5, 7	0.273 Millimoles per liter Standard Deviation 0.5007	0.021 Millimoles per liter Standard Deviation 0.2874	0.226 Millimoles per liter Standard Deviation 0.1254
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Day 2; n=20, 19, 21	0.077 Millimoles per liter Standard Deviation 0.4478	0.103 Millimoles per liter Standard Deviation 0.4625	0.078 Millimoles per liter Standard Deviation 0.5175
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Day 5; n=7, 5, 7	-0.339 Millimoles per liter Standard Deviation 0.3855	-0.033 Millimoles per liter Standard Deviation 0.5333	-0.286 Millimoles per liter Standard Deviation 0.3791
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Day 2; n=20, 19, 21	-0.5 Millimoles per liter Standard Deviation 1.66	-0.8 Millimoles per liter Standard Deviation 1.41	-0.9 Millimoles per liter Standard Deviation 2.13
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Day 5; n=7, 5, 7	-0.7 Millimoles per liter Standard Deviation 1.98	1.0 Millimoles per liter Standard Deviation 1.73	0.4 Millimoles per liter Standard Deviation 1.67
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Day 2; n=20, 19, 21	-0.1 Millimoles per liter Standard Deviation 2.10	0.9 Millimoles per liter Standard Deviation 1.59	0.8 Millimoles per liter Standard Deviation 1.18
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Day 5; n=7, 5, 7	0.4 Millimoles per liter Standard Deviation 1.81	-1.0 Millimoles per liter Standard Deviation 2.00	-0.4 Millimoles per liter Standard Deviation 2.30
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Day 2; n=20, 19, 21	0.078 Millimoles per liter Standard Deviation 0.0590	0.098 Millimoles per liter Standard Deviation 0.0777	0.063 Millimoles per liter Standard Deviation 0.0930
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Day 5; n=7, 5, 7	0.067 Millimoles per liter Standard Deviation 0.0702	0.097 Millimoles per liter Standard Deviation 0.0663	0.068 Millimoles per liter Standard Deviation 0.0867
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Day 2; n=20, 19, 21	0.030 Millimoles per liter Standard Deviation 0.2588	-0.036 Millimoles per liter Standard Deviation 0.2823	0.087 Millimoles per liter Standard Deviation 0.2938
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Day 5; n=7, 5, 7	0.113 Millimoles per liter Standard Deviation 0.3935	-0.207 Millimoles per liter Standard Deviation 0.3073	-0.100 Millimoles per liter Standard Deviation 0.2547
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Day 2; n=20, 19, 21	-0.02 Millimoles per liter Standard Deviation 0.270	0.08 Millimoles per liter Standard Deviation 0.249	-0.01 Millimoles per liter Standard Deviation 0.273
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Day 5; n=7, 5, 7	-0.04 Millimoles per liter Standard Deviation 0.282	-0.26 Millimoles per liter Standard Deviation 0.270	-0.32 Millimoles per liter Standard Deviation 0.377
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Day 2; n=20, 19, 21	-1.0 Millimoles per liter Standard Deviation 2.00	-0.5 Millimoles per liter Standard Deviation 2.06	-0.5 Millimoles per liter Standard Deviation 2.59